<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter B Kang, MD, FAAP, FAAN</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Nordli, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen V Firth, DM, FRCP, FMedSci</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The hereditary peripheral neuropathies have been classified based upon clinical characteristics, mode of inheritance, electrophysiologic features, metabolic defects, and specific genetic markers. The primary hereditary neuropathies predominantly affect peripheral nerves and produce symptoms of peripheral nerve dysfunction.</p><p>Historically, the primary hereditary neuropathies were designated by eponyms that had the connotation of specific clinical features (eg, Charcot-Marie-Tooth disease [CMT] or Dejerine-Sottas disease). However, phenotypic variability resulted in substantial diagnostic confusion.</p><p>The Dyck classification developed in the 1970s helped to define specific types based upon clinical and electrophysiologic features [<a href="#rid1">1</a>]. Many of the primary hereditary neuropathies were divided into hereditary motor sensory neuropathy (HMSN) and hereditary sensory autonomic neuropathy (HSAN). However, the eponym Charcot-Marie-Tooth disease has had a resurgence in popularity, and today the term "CMT" is regarded as being synonymous with HMSN.</p><p>CMT/HMSN is the focus of the current review and for the sake of simplicity will be referred to as CMT for the remainder of this review. This topic will review the genetics, clinical features, and evaluation of CMT. Management and prognosis are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/113945.html" rel="external">"Charcot-Marie-Tooth disease: Management and prognosis"</a>.)</p><p>The primary hereditary sensory autonomic neuropathies, the neuropathies not included in this classification, and the disorders affecting both the central and peripheral nervous systems are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6207.html" rel="external">"Overview of hereditary neuropathies"</a> and  <a class="medical medical_review" href="/z/d/html/6227.html" rel="external">"Hereditary sensory and autonomic neuropathies"</a> and  <a class="medical medical_review" href="/z/d/html/6226.html" rel="external">"Neuropathies associated with hereditary disorders"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>CMT consists of a spectrum of disorders caused by pathogenic variants in various genes whose protein products are expressed in myelin, gap junctions, and/or axonal structures within peripheral nerves [<a href="#rid2">2</a>]. A variety of pathogenic variant types has been associated with CMT, including whole-gene duplications and deletions as well as point pathogenic variants [<a href="#rid3">3,4</a>]. For example, duplication of the <em>PMP22</em> gene causes CMT1A, the most common subtype (approximately 40 percent overall).</p><p>The association of different pathogenic variants within the same gene with various clinical phenotypes is a common finding in this group of peripheral neuropathies. This variability suggests that these disorders represent a spectrum of related phenotypes caused by an underlying defect in peripheral nervous system myelination and axonal function.</p><p>The major categories of CMT are CMT types 1 through 7 as well as an X-linked category, CMTX. Within each category, a specific disease associated with a particular gene is assigned a letter (eg, CMT1A, CMT1B, etc). CMT is genetically heterogeneous with numerous causative genes identified to date [<a href="#rid5">5,6</a>], but the vast majority of cases are attributed to pathogenic variants in just four genes: <em>PMP22</em>, <em>MPZ</em>, <em>GJB1</em>, and <em>MFN2</em>. This genetic distribution was first described in a large cohort of 1024 CMT patients from the United States [<a href="#rid7">7</a>] and confirmed in a subsequent cohort of 1005 patients from Japan [<a href="#rid8">8</a>]. The overall estimated prevalence of CMT is 40 per 100,000 [<a href="#rid9">9</a>], which varies from 10 to 82 per 100,000 in different reports [<a href="#rid10">10</a>]. There is no known ethnic predisposition [<a href="#rid6">6</a>]. CMT types 1 and 2 represent by far the largest proportion of patients, as documented in several studies, including ones from Russia [<a href="#rid11">11</a>] and France [<a href="#rid12">12</a>].</p><p>The most common initial presentation of CMT is distal weakness and atrophy manifesting with foot drop and pes cavus. Sensory symptoms are often present but tend to be less prominent. Later in the course, foot deformities such as hammertoes ensue, along with hand weakness and atrophy  (<a class="graphic graphic_table graphicRef72688" href="/z/d/graphic/72688.html" rel="external">table 1</a>).</p><p>The diagnostic evaluation, despite the widespread availability of genetic testing, still centers on electromyography (EMG) in many cases. Genetic testing is key to confirming the diagnosis after EMG. However, it may be appropriate to skip EMG and go directly to genetic testing in a patient with a strong family history of confirmed CMT, especially when a relative has a known pathogenic variant.</p><p class="headingAnchor" id="H3"><span class="h1">CMT1</span><span class="headingEndMark"> — </span>CMT1 is characterized by peripheral nerve demyelination and an autosomal dominant pattern of inheritance. CMT1A, due to duplication of the <em>PMP22</em> gene, accounts for approximately 70 to 80 percent of CMT1 cases [<a href="#rid11">11,13</a>]. Affected patients typically present in the first or early second decade [<a href="#rid14">14</a>]. Infants with this pathogenic variant may be symptomatic, but these cases are generally classified as congenital hypomyelinating neuropathy or Dejerine-Sottas disease. (See <a class="local">'CMT3'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Early complaints may include frequent sprained ankles caused by distal muscle weakness or difficulty running and keeping up with peers. Physical findings may include areflexia, pes cavus, and distal lower extremity weakness and atrophy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Distal calf muscle atrophy often occurs, causing the classic "stork leg deformity," which tends to become more prominent with disease progression. Walking is clumsy because of both muscle weakness and sensory loss. Sensory loss progresses gradually and may be detected on physical examination via loss of proprioception and vibration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late changes include atrophy of the intrinsic hand and foot muscles. Palpable enlargement of the peripheral nerves may occur secondary to nerve hypertrophy. In addition, kyphosis or scoliosis may develop at later stages of the disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ambulation may be significantly affected, but complete loss of ambulation is uncommon. Life expectancy is normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disease exacerbation can occur in pregnancy, an effect that may be mediated by increased plasma progesterone [<a href="#rid15">15</a>]. (See <a class="local">'Management'</a> below.)</p><p></p><p>Nerve conduction studies (NCS) show severe slowing of conduction velocity in both the motor and sensory nerves, typically with values less than 60 percent of normal. The pattern of slowing is generally uniform, with no conduction block or temporal dispersion. In some cases, sensory responses may be absent. Nerve conduction velocity slowing is present even in asymptomatic infants [<a href="#rid16">16</a>]. Needle electromyography (EMG) examination is typically normal. Frequently, little correlation exists between the electromyographic and clinical findings, as the latter are probably produced primarily by secondary axonal dysfunction [<a href="#rid4">4,17,18</a>].</p><p>Sural nerve biopsy shows demyelination that affects primarily the large nerve fibers. Onion bulbs are a characteristic feature; they reflect repeated demyelination and remyelination and represent redundant Schwann cells, collagen, and fibroblasts. Secondary axonal changes may be present.</p><p class="headingAnchor" id="H4"><span class="h2">Genetics of CMT1</span><span class="headingEndMark"> — </span>CMT1 is caused by mutations in genes that are expressed in Schwann cells, the myelinating cells of the peripheral nervous system [<a href="#rid4">4</a>]. The most common types exhibit autosomal dominant inheritance and have been subdivided into types 1A, 1B, 1C, etc. However, autosomal recessive and X-linked forms also occur [<a href="#rid19">19-22</a>]. (See <a class="local">'X-linked CMT'</a> below.)</p><p class="headingAnchor" id="H4307678"><span class="h3">CMT1A</span><span class="headingEndMark"> — </span>CMT1A is associated with a 1.5 Mb duplication or, less commonly, a single nucleotide variant of the peripheral myelin protein 22 (<em>PMP22</em>) gene on chromosome 17p11.2-p1; duplication leads to overexpression of <em>PMP22</em>, while single nucleotide variants alter distribution of the protein [<a href="#rid3">3,23,24</a>]. Interestingly, patients with a 1.5 Mb deletion at this site develop hereditary neuropathy with pressure palsy. (See  <a class="medical medical_review" href="/z/d/html/6227.html" rel="external">"Hereditary sensory and autonomic neuropathies"</a>.)</p><p>Patients with single nucleotide variants usually have more prominent clinical manifestations. In these patients, <em>PMP22</em> partially accumulates in the Schwann cells rather than being inserted in the myelin sheath, as occurs with gene duplication [<a href="#rid24">24</a>].</p><p>In addition to the typical findings discussed above, patients with CMT1A may have associated sleep apnea [<a href="#rid25">25,26</a>]. In one report, 13 asymptomatic family members of an index patient with CMT and sleep apnea were investigated for these disorders. Eleven of the 14 (including the index patient) had <em>PMP22</em> duplications on chromosome 17; all 11 also had sleep apnea [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H3895527630"><span class="h3">Hereditary neuropathy with liability to pressure palsy</span><span class="headingEndMark"> — </span>Hereditary neuropathy with liability to pressure palsy (HNPP; tomaculous neuropathy), a recurrent, episodic demyelinating neuropathy, is an autosomal dominant disorder associated with <em>PMP22</em> deletions and single nucleotide variants that is allelic to CMT1A. Affected patients typically present with isolated nerve palsies in areas frequently affected by compression or mild trauma. Symptoms first appear in the second decade in most patients, but they can occur in younger children or be delayed until into the third decade [<a href="#rid27">27-29</a>]. Single nerve palsies typically appear sequentially, resolving in days to months, and may be associated with persistent motor deficits in various nerve distributions.</p><p>The most frequently affected nerves are those at common sites of trauma or entrapment and include the axillary, median, radial, ulnar, and peroneal nerves, along with the brachial plexus. Other findings may include cranial nerve involvement, sensorineural deafness, and scoliosis. In one series of 70 patients, nerve involvement in episodes of palsy occurred with the following frequencies [<a href="#rid28">28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Peroneal nerve – 36 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Ulnar nerve – 28 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Brachial plexus – 20 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Radial nerve – 13 percent</p><p></p><p>Atypical phenotypes of HNPP include a polyneuropathy resembling chronic inflammatory demyelinating polyneuropathy [<a href="#rid30">30</a>] and presentations involving generalized weakness and muscle cramps [<a href="#rid31">31</a>], musculoskeletal pain [<a href="#rid32">32</a>], or low back pain with radicular symptoms [<a href="#rid33">33</a>]. Central nervous system white matter lesions have been reported in isolated patients as well as several members of a large family with HNPP [<a href="#rid34">34,35</a>].</p><p>HNPP results in focal slowing of motor nerve conduction velocities. Sural nerve biopsy shows focal myelin thickening (tomacula) on light microscopy. These lesions are best seen with teased fiber preparations and appear as enlarged sausage-shaped thickenings of the myelin sheath [<a href="#rid36">36</a>].</p><p>HNPP is an autosomal dominant disorder associated with <em>PMP22</em> gene pathogenic variants. In approximately 80 percent of HNPP cases, there is a 1.5 Mb deletion in chromosome 17p11.2 that results in reduced expression of <em>PMP22</em> [<a href="#rid28">28,37-39</a>]. The deletion corresponds to the duplicated region of <em>PMP22</em> present in CMT1A. Approximately 20 percent of patients with HNPP have single nucleotide variants or small deletions in <em>PMP22</em>, and sporadic cases with de novo deletions have been described [<a href="#rid28">28,39-41</a>]. <em>PMP22</em> pathogenic variants may slow nerve conduction by disrupting myelin junctions [<a href="#rid42">42</a>]. In one report of seven children with <em>PMP22</em> deletions and early-onset HNPP, a coexisting Ile92Val polymorphism in the <em>LITAF</em> gene was present in six children, suggesting that this polymorphism leads to an early-onset HNPP phenotype when accompanied by a <em>PMP22</em> deletion [<a href="#rid29">29</a>].</p><p>On electrodiagnostic testing, patients with HNPP will typically display signs of a demyelinating neuropathy even while asymptomatic, including subclinical carpal tunnel syndrome. There should be multiple signs of demyelination if enough nerves are studied [<a href="#rid43">43</a>]. Depending on the clinical presentation, it may make sense to perform these studies prior to sending out genetic testing.</p><p>The treatment of HNPP is conservative and primarily consists of strategies to avoid mild trauma and compression at vulnerable sites. This may entail special accommodations at school or work.</p><p class="headingAnchor" id="H4307685"><span class="h3">CMT1B</span><span class="headingEndMark"> — </span>CMT1B, originally known as peroneal muscular atrophy, is most often caused by single nucleotide variants in the myelin protein zero (<em>MPZ</em>) gene on chromosome 1q22, which cause overexpression of the major myelin structural protein [<a href="#rid44">44,45</a>]. <em>MPZ</em> is one of the four genes that cause the vast majority of cases of CMT. There appear to be three distinctive phenotypic subgroups of pathogenic <em>MPZ</em> variants [<a href="#rid46">46-48</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An early-onset, severe demyelinating neuropathy with very slow nerve conduction velocities (&lt;10 m/second)</p><p class="bulletIndent1"><span class="glyph">●</span>A late-onset axonal neuropathy with slightly reduced or normal nerve conduction velocities, classified as CMT2I (see <a class="local">'Additional CMT2 subtypes'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>A dominant intermediate form of CMT, DI-CMTD [<a href="#rid49">49,50</a>]</p><p></p><p>Normal peripheral nerve myelination depends upon strict dosage of <em>MPZ</em>, and overexpression may be deleterious [<a href="#rid51">51,52</a>]. Transgenic mice containing extra copies of the <em>MPZ </em>gene manifest a dose-dependent, dysmyelinating neuropathy [<a href="#rid51">51</a>]. In six individuals with CMT1 from one family, comparative genome hybridization analysis revealed an increased gene dosage, estimated to be five copies, of the entire <em>MPZ</em> gene and flanking genes [<a href="#rid53">53</a>]. Pathogenic variants of <em>MPZ</em> gene introns that disrupt normal protein splicing have also been identified in a small number of families with CMT1B [<a href="#rid54">54</a>].</p><p><em>MPZ</em> is normally expressed on the cell membrane of Schwann cells and plays a major role in myelin membrane adhesion [<a href="#rid55">55,56</a>]. In one family with CMT1B, in vitro fluorescence analysis demonstrated that mutant <em>MPZ</em> was localized in the endoplasmic reticulum and Golgi apparatus rather than on the cell membrane [<a href="#rid57">57</a>]. In addition, the adhesiveness of cells expressing mutant <em>MPZ</em> was diminished compared with controls.</p><p class="headingAnchor" id="H4307635"><span class="h3">Additional CMT1 subtypes</span></p><p class="bulletIndent1"><span class="glyph">●</span>CMT1C is caused by pathogenic variants in the lipopolysaccharide-induced tumor necrosis factor-alpha factor (<em>LITAF</em>) gene, also known as <em>SIMPLE</em>, which is located at chromosome 16p.13.1-p12.3 [<a href="#rid58">58,59</a>]. <em>LITAF</em> is widely expressed and encodes a protein that may play a role in protein degradation pathways. The clustering of pathogenic variants associated with CMT1C suggests that a domain of <em>LITAF</em> may be important in peripheral nerve function. In contrast with other known genes that cause CMT1, the level of expression of the <em>LITAF </em>transcript did not change during development or in response to lung injury, suggesting a potential new mechanism of peripheral nerve perturbation resulting in demyelinating neuropathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT1D is caused by pathogenic variants in the early growth response 2 (<em>EGR2</em>) gene on chromosome 10q21.1-q22.1 [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT1E is characterized by a classic CMT phenotype and sensorineural hearing loss [<a href="#rid61">61</a>]. The cause is single nucleotide variants in the <em>PMP22</em> gene [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT1F is caused by pathogenic variants in the neurofilament light (<em>NEFL</em>) gene on chromosome 8p21 [<a href="#rid63">63</a>]. Pathogenic variants in the same gene can cause an axonal form classified as CMT2E. (See <a class="local">'CMT2'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Roussy-Levy syndrome, first described in 1926, is a CMT1 phenotype with manifestations that include postural tremor, gait ataxia, distal muscle atrophy, pes cavus, areflexia, and mild distal sensory loss [<a href="#rid64">64,65</a>]. Genetic testing of members of the original family identified a heterozygous missense variant for the extracellular domain of the <em>MPZ</em> gene, indicating CMT1B disease [<a href="#rid64">64</a>]. However, testing in another large family with the same phenotype found a partial duplication at chromosome 17p11.2, indicating that it is also allelic with CMT1A [<a href="#rid65">65</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h1">CMT2</span><span class="headingEndMark"> — </span>CMT2 is characterized by primarily axonal damage and an autosomal dominant mode of inheritance. A systematic review of epidemiologic studies found that CMT2 accounts for 12 to 36 percent of all CMT cases [<a href="#rid10">10</a>].</p><p>The axonal injury is reflected in diminished motor amplitudes on nerve conduction studies, with signs of chronic reinnervation on needle electromyography (EMG). Sural nerve biopsy shows axonal degeneration without hypertrophic features; demyelination with onion bulb formation does not occur or is minimal [<a href="#rid66">66</a>]. These features distinguish CMT2 from CMT1 [<a href="#rid66">66</a>].</p><p>The classic clinical manifestations of CMT2 include distal weakness, atrophy, sensory loss, decreased deep tendon reflexes, and variable foot deformity [<a href="#rid67">67</a>]. The onset of symptoms usually is in the second or third decade of life, a bit later than in CMT1. The clinical course is similar to that of CMT1, but sensory symptoms, with loss of vibration and proprioception, may be more prominent, and peripheral nerves are not palpably enlarged. Distal trophic ulcerations in the feet may occur.</p><p>An early-onset form of CMT2 becomes clinically apparent before the child reaches five years of age. Weakness progresses rapidly, with loss of strength below the knees by the second decade. Sensory symptoms are present but overshadowed by the motor weakness. Ambulation often is lost by the time the child reaches mid-teens.</p><p>Possible late-onset forms of CMT2 presenting from 35 to 85 years of age (median age 57) have been described in six families [<a href="#rid68">68</a>]. The electrophysiologic findings were primarily those of axonal involvement. The late-onset forms are likely to be genetically heterogeneous. Autosomal dominant inheritance was demonstrated in two of the families, while inheritance patterns were unclear in the remaining four families.</p><p class="headingAnchor" id="H8"><span class="h2">Genetics of CMT2</span><span class="headingEndMark"> — </span>Autosomal dominant pathogenic variants are responsible for most cases of CMT2, though autosomal recessive inheritance can occur [<a href="#rid69">69-71</a>]. However, the genetic basis of CMT2 is incompletely described. A retrospective study from a neuropathy clinic published in 2012, at the dawn of the next generation sequencing era, reported that, of 115 patients with CMT2, pathogenic variants were identified in only 25 percent [<a href="#rid72">72</a>].</p><p>There are many different subtypes of CMT2, as discussed in the sections that follow.</p><p class="headingAnchor" id="H4307628"><span class="h3">CMT2A</span><span class="headingEndMark"> — </span>CMT2A is the most common CMT2 phenotype and accounts for approximately 20 percent of axonal CMT cases and 5 percent of all CMT [<a href="#rid47">47</a>]. The gene most commonly implicated in CMT2A is mitochondrial fusion protein mitofusin 2 (<em>MFN2</em>) [<a href="#rid67">67,73-76</a>]. The inheritance mode is autosomal dominant in most cases. However, some studies suggest that some <em>MFN2</em> pathogenic variants cause a form of early-onset CMT with apparent autosomal recessive inheritance [<a href="#rid77">77,78</a>].</p><p>An early report identified a pathogenic variant in the kinesin family member 1B gene (<em>KIF1B</em>) in a single Japanese family [<a href="#rid79">79</a>], but this pathogenic variant has not been confirmed in other CMT2A families and may represent a benign rare polymorphism [<a href="#rid80">80</a>].</p><p class="headingAnchor" id="H4307590"><span class="h3">Additional CMT2 subtypes</span><span class="headingEndMark"> — </span>Other CMT2 subtypes are rare and difficult to diagnose [<a href="#rid47">47</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>CMT2B is characterized by predominant sensory involvement; it maps to chromosome 3q21.3 and is associated with pathogenic variants in RAS-associated protein 7 (<em>RAB7</em>) [<a href="#rid81">81,82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT2C is characterized by distal muscle weakness, vocal cord paralysis, mild sensory impairment, and axonal neuropathy [<a href="#rid83">83,84</a>]. It maps to chromosome 12q24.1 and is associated with pathogenic variants in the <em>TRPV4</em> gene [<a href="#rid85">85,86</a>]. <em>TRPV4</em> pathogenic variants also cause congenital distal spinal muscular atrophy and scapuloperoneal spinal muscular atrophy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT2D is characterized by predominant hand weakness and atrophy with a locus on chromosome 7p15 [<a href="#rid87">87</a>]. Associated pathogenic variants have been identified in the glycyl tRNA synthetase (<em>GARS</em>) gene [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT2E is caused by pathogenic variants in the <em>NEFL</em> gene linked to chromosome 8p [<a href="#rid89">89-91</a>]. In several families with CMT2E, electrophysiological studies showed features consistent with a mixed axonal and demyelinating neuropathy, while pathological studies revealed an axonopathy with giant axons, accumulation of disorganized neurofilaments, and significant secondary demyelination [<a href="#rid92">92</a>]. Other pathogenic variants in the <em>NEFL</em> gene cause a predominantly demyelinating neuropathy classified as CMT1F. (See <a class="local">'CMT1'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT2F is characterized by a classic CMT phenotype with a locus on chromosome 7q11.23 [<a href="#rid93">93</a>] and is associated with missense variants in the heat shock 27kDa protein 1 (<em>HSPB1</em>) gene [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT2I is a clinically distinct late-onset CMT phenotype associated with pathogenic variants in the <em>MPZ</em> gene and characterized by axonal polyneuropathy, prominent sensory involvement, pupillary abnormalities, and hearing loss [<a href="#rid46">46,95-98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT2K is a form of axonal CMT with autosomal dominant or recessive inheritance caused by pathogenic variants in the <em>GDAP1</em> gene [<a href="#rid99">99-101</a>]. Pathogenic variants in <em>GDAP1</em> have also been identified in patients with CMT4A, a demyelinating form. (See <a class="local">'CMT4'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT2L is characterized by a classic CMT phenotype and maps to chromosome 12q24.23 [<a href="#rid102">102</a>] and is associated with pathogenic variants in the heat shock protein 8 (<em>HSPB8</em>) gene [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT2M is caused by pathogenic variants in the <em>DNM2</em> gene [<a href="#rid104">104,105</a>]. <em>DNM2</em> has also been associated with an autosomal dominant form of intermediate CMT, known as DI-CMTB [<a href="#rid106">106,107</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT2P is characterized by a classic axonal CMT phenotype. Originally designated CMT2G and mapped to chromosome 12q12-q13 [<a href="#rid108">108</a>], the disease locus was later reassigned to 9q33.3-q34.1 and the cause was related to pathogenic variants in the leucine-rich repeat and sterile alpha motif-containing 1 (<em>LRSAM1</em>) gene [<a href="#rid109">109</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT2S is caused by truncating and missense variants in the <em>IGHMBP2</em> gene and is characterized by slowly progressive weakness, muscle atrophy, and sensory loss without significant respiratory compromise [<a href="#rid110">110,111</a>]. Pathogenic variants in <em>IGHMBP2</em> are also the cause of spinal muscular atrophy with respiratory distress type 1 (<em>SMARD1</em>). (See  <a class="medical medical_review" href="/z/d/html/6146.html" rel="external">"Spinal muscular atrophy", section on 'Spinal muscular atrophy with respiratory distress type 1'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT2T is caused by <em>MME</em> gene pathogenic variants, which were identified in 10 unrelated patients from Japan with late-onset autosomal recessive CMT2 [<a href="#rid112">112</a>]. The late-onset axonal phenotype for biallelic pathogenic variants was confirmed in a cohort from Spain [<a href="#rid113">113</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT2 caused by a mitochondrially encoded ATP synthase 6 (<em>MT-ATP6</em>) gene pathogenic variant, which does not yet have a subtype letter designation, is characterized by onset in the first to second decade, variable severity, an initial pure motor neuropathy that evolves to a motor-predominant axonal neuropathy in the third to fourth decades, and early proximal leg weakness regardless of the presence of distal weakness [<a href="#rid114">114</a>]. Rapid clinical deterioration may occur in the setting of a febrile infectious illness. In a cohort of 270 patients with a clinical phenotype consistent with CMT2, a pathogenic variant in the <em>MT-ATP6</em> gene was identified in 1 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT2DD is caused by dominant pathogenic variants in <em>ATP1A1</em> that are associated with dysfunction of the sodium-potassium pump, leading to distal extremity weakness with preserved proximal strength, vibratory sensory loss, axonal loss on electrophysiologic studies, and variable age of onset from childhood to adulthood [<a href="#rid115">115</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h1">X-LINKED CMT</span><span class="headingEndMark"> — </span>There are X-linked dominant and X-linked recessive forms of CMT involving different loci [<a href="#rid71">71</a>]. Together, the X-linked forms account for approximately 10 to 15 percent of all CMT cases.</p><p class="headingAnchor" id="H4308332"><span class="h2">CMTX1</span><span class="headingEndMark"> — </span>CMTX1, the X-linked dominant form of CMT, is the second most common form of CMT after CMT1A, accounting for 7 to 12 percent of all CMT cases [<a href="#rid13">13,71,116,117</a>]. It is the most common X-linked form of CMT, accounting for approximately 50 percent of X-linked cases [<a href="#rid118">118</a>]. (See <a class="local">'CMT1'</a> above.)</p><p>CMTX1 is caused by pathogenic variants in the gap junction protein beta 1 (<em>GJB1</em>) gene, also known as the connexin 32 gene, on chromosome Xq13.1 [<a href="#rid20">20-22,66</a>]. The gene is expressed in myelinating Schwann cells but not incorporated into the myelin sheath [<a href="#rid119">119</a>]. Most <em>GJB1</em> pathogenic variants are thought to cause disability by a loss of function of the gap junction protein connexin 32 [<a href="#rid120">120</a>].</p><p>The symptoms of CMTX1 are more prominent and begin earlier in males [<a href="#rid121">121</a>], who generally present in infancy or later in childhood with gait problems (eg, toe walking, flat footed walking, falls, difficulty running); some present in infancy with foot deformities (pes planus or pes cavus) [<a href="#rid122">122</a>]. Less common features include tremor, hand weakness, and sensorineural deafness. However, all patients remain ambulatory. Reflexes are lost at the ankles in all cases, whereas patellar reflexes are retained in approximately one-half of females. The neuropathy may be asymmetric and therefore mimic an acquired immune-mediated neuropathy [<a href="#rid47">47</a>].</p><p>Children and young adults with CMTX1 can experience transient central nervous system manifestations, including limb weakness (eg, hemiparesis, quadriparesis, or monoparesis), dysarthria, dysphagia, ataxia, or combinations of deficits [<a href="#rid123">123-126</a>]. At presentation with these stroke-like episodes, brain magnetic resonance imaging (MRI) typically shows reversible lesions on diffusion-weighted, T2, and fluid-attenuated inversion recovery (FLAIR) sequences in the deep white matter, predominantly in the posterior brain regions or splenium of the corpus callosum. In some cases, the nature of the transient attacks and the MRI appearance of associated brain lesions are reminiscent of acute disseminated encephalomyelitis. (See  <a class="medical medical_review" href="/z/d/html/6184.html" rel="external">"Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and diagnosis", section on 'Neuroimaging'</a>.)</p><p>Other reports have described patients with X-linked CMT, mainly CMTX1, who developed clinical features and central nervous system demyelination compatible with a diagnosis of multiple sclerosis [<a href="#rid127">127</a>]. (See  <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6229.html" rel="external">"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis"</a>.)</p><p>The pathophysiology typically of CMTX1 includes features of both demyelination and axon loss, and this is reflected in neurophysiologic studies. Nerve conduction velocities are moderately slowed but not to the same degree as in autosomal dominant CMT1 [<a href="#rid128">128</a>]. Demyelination and axonal loss is observed histologically, but onion bulb formation is minimal.</p><p class="headingAnchor" id="H4308339"><span class="h2">Additional CMTX subtypes</span></p><p class="bulletIndent1"><span class="glyph">●</span>CMTX2 is the X-linked recessive form that maps to Xp22 [<a href="#rid129">129,130</a>]. In the one described family, carrier females were unaffected. In males, the phenotype was notable for infantile onset, atrophy and weakness of lower leg muscles, areflexia, and pes cavus. Intellectual disability was present in some. Electrophysiologic studies demonstrated both demyelination and axonal involvement. No causative gene has been identified [<a href="#rid131">131</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMTX3 is also X-linked recessive and is caused by a 78 kb insertion at chromosome Xq27.1 that originates from chromosome 8 [<a href="#rid118">118,129,130,132</a>]. In two described families, the phenotype was notable for juvenile onset, distal atrophy with weakness, and normal intelligence, with both demyelination and axonal features by electrophysiologic studies [<a href="#rid129">129,130</a>]. In a third family, disease severity was variable between affected males, with widely ranging nerve conduction velocities [<a href="#rid118">118</a>]. Symptoms began in the legs during the first decade of life, and arm involvement followed approximately 10 years later in two-thirds of patients. Pain and paresthesia were frequently the first sensory symptoms. Pyramidal signs, tremor, and hearing loss were not observed. Female carriers were usually asymptomatic. A series of 11 families demonstrated early onset including foot deformity during infancy, severe hand weakness, and rapid progression during childhood, with primarily demyelinating features on electrophysiological testing [<a href="#rid133">133</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cowchock syndrome (CMTX4; CMT with deafness and intellectual disability) is a rare form of infantile-onset axonal X-linked CMT [<a href="#rid134">134</a>]. Affected males demonstrated severe muscle weakness associated with deafness and intellectual disability. Females demonstrated only minor abnormalities involving sensory nerve conduction, electromyography, and hearing. The disorder is caused by pathogenic variants in the apoptosis inducing factor mitochondria-associated 1 (<em>AIFM1</em>) gene on chromosome Xq26 [<a href="#rid135">135</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMTX5 is an X-linked recessive disorder with deafness and optic neuropathy that has been reported in a Korean family [<a href="#rid136">136</a>]; the disease is caused by pathogenic variants in the phosphoribosyl pyrophosphate synthetase 1 (<em>PRPS1</em>) gene [<a href="#rid137">137</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMTX6 is an X-linked dominant disorder described in a family from Australia and characterized by an axonal-predominant motor and sensory form of CMT with childhood onset and gradual disease progression in affected males [<a href="#rid138">138</a>]. Carrier females were either mildly symptomatic or asymptomatic. The cause is pathogenic variants in the pyruvate dehydrogenase kinase 3 (<em>PDK3</em>) gene.</p><p></p><p class="headingAnchor" id="H11"><span class="h1">CMT3</span><span class="headingEndMark"> — </span>Two disorders, Dejerine-Sottas syndrome and congenital hypomyelinating neuropathy, are classified as CMT3. These are severe, early-onset peripheral neuropathies that are thought to be caused by an inability of the Schwann cells to produce normal myelin, resulting in thin, poorly formed myelin. On histologic examination, patients with Dejerine-Sottas syndrome have thin myelin sheaths and large onion bulb formation, whereas those with congenital hypomyelinating neuropathy show essentially absent myelin without evidence of inflammation, myelin breakdown, or onion bulbs.</p><p>Historically, Dejerine-Sottas syndrome and congenital hypomyelinating neuropathy were considered to be distinct clinical and histologic entities. However, their genetic etiologies overlap considerably and the distinction between the two diseases is becoming blurred.</p><p class="headingAnchor" id="H12"><span class="h2">Dejerine-Sottas syndrome</span><span class="headingEndMark"> — </span>Dejerine-Sottas syndrome is a severe demyelinating neuropathy that presents in early infancy with hypotonia. The phenotype is characterized by delayed motor development, prominent sensory loss, distal followed by proximal weakness, absent reflexes, ataxia, and profound slowing of nerve conduction velocities to ≤10 m/second. Scoliosis appears early and progresses with time, and contractures develop. Progression is slow, often with ambulation maintained through adult life [<a href="#rid139">139</a>]. Although Dejerine-Sottas syndrome can still be distinguished clinically from classic CMT and congenital hypomyelinating neuropathy, genetic overlap with these other phenotypes has blurred the boundaries among these subtypes of inherited neuropathies [<a href="#rid140">140</a>].</p><p>Autosomal recessive and several dominant heterozygous forms of Dejerine-Sottas syndrome have been described, affecting genes that are also involved in CMT1 and CMT4. They include pathogenic variants in the <em>PMP22</em> gene (also found in CMT1A) [<a href="#rid52">52,66,141,142</a>], the <em>MPZ</em> gene (also found in CMT1B) [<a href="#rid52">52,66</a>], and the <em>EGR2</em> gene (as perhaps occurs in CMT1C) [<a href="#rid143">143,144</a>]. In one series of nine patients, for example, four novel single-nucleotide variants occurred in <em>PMP22</em> and two in <em>MPZ</em>; two cases were autosomal dominant [<a href="#rid52">52</a>]. Recessive inheritance involving the <em>PRX</em> gene (the cause of CMT4F) was described in three unrelated patients with Dejerine-Sottas neuropathy [<a href="#rid145">145</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Congenital hypomyelinating neuropathy</span><span class="headingEndMark"> — </span>Congenital hypomyelinating neuropathy presents at birth with profound hypotonia and contractures. Conduction velocities are either absent or extremely slow. Feeding difficulties and respiratory distress often lead to death in infancy [<a href="#rid146">146</a>]. However, several cases that exhibited spontaneous improvement in motor function with increasing age have been reported [<a href="#rid147">147-149</a>]; one patient completely recovered by four months [<a href="#rid147">147</a>].</p><p>Congenital hypomyelinating neuropathy is genetically heterogeneous. Most cases are thought to be caused by pathogenic variants in either <em>PMP22</em> or <em>MPZ</em> [<a href="#rid149">149-152</a>]. Other pathogenic variants have been described in <em>EGR2</em> [<a href="#rid60">60</a>] and <em>MTMR2</em> [<a href="#rid153">153</a>]. Genetic transmission in most cases is autosomal dominant, but rare autosomal recessive cases have been reported.</p><p class="headingAnchor" id="H14"><span class="h1">CMT4</span><span class="headingEndMark"> — </span>CMT4 is a rapidly expanding heterogeneous group of autosomal recessive demyelinating motor sensory neuropathies. These autosomal recessive forms of CMT are rare, clinically more severe, and less likely to result from pathogenic variants in structural myelin proteins than the autosomal dominant forms. Individuals with CMT4 have a typical CMT phenotype of distal muscle weakness and atrophy associated with sensory loss and foot deformities (ie, pes cavus) [<a href="#rid154">154</a>]. Conduction velocities are typically slow (&lt;40 m/second) on nerve conduction studies.</p><p>Several subtypes of CMT4 disease are described based upon electrophysiologic, pathologic, and genetic criteria.</p><p class="bulletIndent1"><span class="glyph">●</span>CMT4A was identified in Tunisian consanguineous families. It presents in early childhood with distal weakness and mild sensory loss [<a href="#rid155">155</a>]. The neuropathy is rapidly progressive. Patients often are incapacitated by the fourth decade. Hypomyelination, loss of myelinated fibers, and basal laminal onion bulbs are present. Conduction velocities are moderately reduced. The disease has been mapped to chromosome 8q13-q21.1. Pathogenic variants have been identified in the <em>GDAP1</em> gene [<a href="#rid156">156,157</a>]. <em>GDAP1</em> appears to be predominately expressed in neurons but not in Schwann cells and localized in mitochondrial membranes [<a href="#rid158">158</a>]. This finding suggests that mitochondrial abnormalities may cause CMT4A [<a href="#rid158">158</a>]. Of note, there have been several reports of patients with recessive <em>GDAP1</em> pathogenic variants who have features of both demyelination and axonal loss, suggesting that some of these patients have mixed physiology [<a href="#rid159">159,160</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT4B is divided into several subtypes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CMT4B1 was first described in a consanguineous Italian family [<a href="#rid161">161,162</a>]. The disease presented in patients at age 2 to 4 with distal and proximal weakness with moderate sensory loss and frequent involvement of cranial nerves [<a href="#rid163">163</a>]. Histologic features included loss of myelin fibers, segmental demyelination and remyelination, and numerous onion bulbs; focally folded myelin sheaths were present in peripheral nerves. Conduction velocity was slow. The causative <em>MTMR2</em> gene is on chromosome 11q22-23 [<a href="#rid164">164</a>]. CMT4B1 disease is more severe than CMT4B2 due to earlier onset and more frequent motor milestones delay, wheelchair use, and respiratory involvement [<a href="#rid165">165</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CMT4B2 shares the same morphological features on nerve biopsy as CMT4B1 but is generally less severe and differs in age of onset and clinical presentation [<a href="#rid165">165</a>]. The causative <em>SBF2</em> gene is on chromosome 11p15 [<a href="#rid166">166,167</a>]. The age of onset ranged from 4 to 13 years old [<a href="#rid166">166-170</a>]. Distal weakness was prominent on presentation, with proximal weakness developing only after several years. Motor nerve conduction velocities were similarly slowed. Early-onset glaucoma was a feature in some families [<a href="#rid167">167,169,170</a>]. An Italian family was also been reported with CMT4B2 [<a href="#rid171">171,172</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CMT4B3, described in a Korean family, has a similar though less severe phenotype compared with CMT4B1 and CMT4B2 [<a href="#rid173">173</a>]. It is caused by compound heterozygous pathogenic variants in the <em>SBF1</em> gene on chromosome 22q13.33. The <em>SBF1</em> gene is structurally similar to the <em>SBF2</em> gene associated with CMT4B2.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT4C was first described in Algerian families with severe spinal deformities and weakness in childhood and adolescence [<a href="#rid174">174-176</a>] and was later reported in various ethnic backgrounds, including European, African American, Native American, Chinese, Indian, Japanese, Korean, and Norwegian populations [<a href="#rid177">177-182</a>]. Scoliosis is a variable but sometimes severe manifestation that may require operative correction at an early age. Loss of myelinated fibers and some classic onion bulbs are present on nerve pathology. Motor nerve conduction velocity is slowed. CMT4C appears to account for approximately 20 percent of cases of autosomal recessive demyelinating CMT and is associated with pathogenic variants in the <em>SH3TC2</em> gene on chromosome 5q32 [<a href="#rid183">183,184</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT4D is also known as hereditary motor and sensory neuropathy-Lom (HMSNL) and is one of the more common autosomal recessive forms. It occurs in divergent Romani groups descended from a small founder population [<a href="#rid185">185</a>]. CMT4D is an early-onset neuropathy that presents with muscle weakness and wasting, skeletal deformities, sensory loss, and severe reduction in nerve conduction velocities. Neural deafness develops during the second or third decade of life. Slow motor nerve conduction velocity occurs and onion bulbs are present in peripheral nerves. The founder pathogenic variant involves the <em>NDRG1</em> gene on chromosome 8q24.3 [<a href="#rid186">186</a>]. <em>NDRG1</em> is ubiquitously expressed, with particularly high levels in Schwann cells, and may play a role in growth arrest and cell differentiation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT4E corresponds to a congenital hypomyelinating neuropathy caused by a homozygous missense variant in the early growth response 2 gene (<em>EGR2</em>) on chromosome 10q21-22 [<a href="#rid60">60</a>]. Distal weakness is present at birth. Myelin sheaths are thin or absent and onion bulbs are present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT4F was found in a large consanguineous Lebanese family [<a href="#rid187">187</a>]. Onset is in early childhood, with distal muscle weakness and severe sensory loss. Nerve conduction studies revealed the total absence of any sensory or motor evoked response in the upper and lower limbs. Nerve pathology showed severe depletion of myelinated fibers and multiple small onion bulbs. The defective gene (<em>PRX</em>) encodes periaxin, a protein of myelinating Schwann cells [<a href="#rid145">145,187</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT4G, originally termed "hereditary motor and sensory neuropathy – Russe" and described in Romany families, is characterized by childhood onset of leg weakness followed later by arm weakness [<a href="#rid188">188,189</a>]. Accompanying manifestations include distal sensory loss with areflexia, pes cavus. The disorder is caused by pathogenic variants in the hexokinase 1 (<em>HK1</em>) gene [<a href="#rid190">190</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT4H was described in Lebanese and Algerian families as a severe form of CMT with onset in the first two years of life [<a href="#rid191">191</a>]. Major features include unsteady gait, loss of reflexes, scoliosis, and severe demyelinating neuropathy [<a href="#rid191">191</a>]. It is caused by pathogenic variants in the <em>FGD4</em> gene on chromosome 12p11.2 [<a href="#rid192">192,193</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMT4J was first identified in four unrelated patients as a severe form of childhood-onset CMT [<a href="#rid194">194</a>]. Nerve pathology from one patient showed axonal loss and evidence of demyelination and remyelination. In a subsequent report, two siblings with adult-onset CMT4J developed a progressive asymmetric paralysis that clinically resembled motor neuron disease [<a href="#rid195">195</a>]. Neurophysiologic testing showed severe and widespread denervation, while nerve pathology from one sibling revealed severe loss of myelinated nerve fibers [<a href="#rid195">195</a>]. In these families, CMT4J was caused by pathogenic variants in the <em>FIG4</em> gene on chromosome 6q21 [<a href="#rid194">194</a>].</p><p></p><p>In addition to these designated CMT4 subtypes, a study of two families with genetically undefined CMT4 identified <em>SURF1</em> gene variants as the probable cause [<a href="#rid196">196</a>]. Additional features such as lactic acidosis, brain magnetic resonance imaging abnormalities, and cerebellar ataxia developed in affected individuals consistent with the role of this gene as an assembly factor of the mitochondrial respiratory chain complex IV.</p><p>A novel form of autosomal recessive CMT has been associated with pathogenic variants in <em>MCM3AP</em>. Four families were found to have primarily axonal neuropathies while another family was found to have primarily demyelinating neuropathies, with seven of nine affected individuals having mild-to-moderate intellectual disability [<a href="#rid197">197</a>].</p><p class="headingAnchor" id="H23"><span class="h1">HMSN/CMT 5, 6, AND 7</span><span class="headingEndMark"> — </span>Hereditary motor sensory neuropathy (HMSN) types 5, 6, and 7 were used in the 1975 Dyck classification, but these disorders are referred to more commonly by the associated symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span>HMSN 5 refers to patients with autosomal dominant spastic paraparesis with sensory neuropathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HMSN 6 refers to patients with dominant or recessive optic atrophy and motor sensory neuropathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HMSN 7 refers to patients with retinitis pigmentosa and motor sensory neuropathy.</p><p></p><p class="headingAnchor" id="H877051877"><span class="h1">INTERMEDIATE CMT</span><span class="headingEndMark"> — </span>Intermediate CMT is an uncommon CMT variant characterized by mixed axonal-demyelinating physiology. Several X-linked forms of CMT are well-known to have these features. There has been controversy among experts regarding the existence and classification of this form of CMT [<a href="#rid198">198,199</a>], especially for the autosomal subtypes, and thus whenever possible these entities are grouped in with the more traditional categories of CMT described above. Genes unique to intermediate CMT are noted below.</p><p>This intermediate group is further distinguished from CMT1 by the absence of clinically observed nerve hypertrophy [<a href="#rid200">200</a>]. Nerve conduction studies (NCS) generally reveal median nerve motor conduction velocities of 25 to 45 m/second, although values may vary between different laboratories.</p><p class="bulletIndent1"><span class="glyph">●</span>Dominant intermediate CMT type A (DI-CMTA) has been linked to a locus on chromosome 10q24.1-q25.1, but the causative gene has yet to be identified [<a href="#rid201">201</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dominant intermediate CMT type C (DI-CMTC) is caused by pathogenic variants in the tyrosyl-tRNA synthetase (<em>YARS</em>) gene [<a href="#rid202">202,203</a>].</p><p></p><p>Several types of intermediate CMT are inherited in an autosomal recessive manner, including those associated with pathogenic variants in <em>GDAP1</em>, <em>KARS</em>, and <em>PLEKKHG5</em>. See CMT4 section above for details on RI-CMTA (<em>GDAP1</em>). (See <a class="local">'CMT4'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Recessive intermediate CMT type B (RI-CMTB) is caused by pathogenic variants in the lysyl-tRNA synthetase (<em>KARS</em>) gene [<a href="#rid204">204</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recessive intermediate CMT type C (RI-CMTC) is caused by pathogenic variants in the pleckstrin homology and RhoGEF domain containing G5 (<em>PLEKHG5</em>) gene [<a href="#rid205">205,206</a>].</p><p></p><p class="headingAnchor" id="H3306886387"><span class="h1">EVALUATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>A comprehensive history and physical examination remain the core of ascertainment of and evaluation for cases of CMT (see <a class="local">'When to suspect CMT'</a> below). Genetic testing is key to confirming the diagnosis after electrodiagnostic testing. In a patient with a family history of confirmed CMT, bypassing electrodiagnostic testing in favor of immediate genetic testing may be appropriate, especially when a relative has a known pathogenic variant. However, inheritance patterns can be obscured because of the highly variable expression of CMT, such that oligosymptomatic relatives may escape detection [<a href="#rid207">207</a>]. In addition, sporadic CMT is common and may be caused by de novo pathogenic variants.</p><p>Despite the widespread availability of genetic testing, electrodiagnostic testing remains important in many cases. Premature genetic testing may result in inappropriate use of expensive resources on patients who turn out to have other diagnoses, such as idiopathic pes cavus.</p><p>Nerve biopsy is rarely performed today in the diagnostic evaluation of CMT. However, it may still play a role when the clinical presentation is atypical and/or the electromyography (EMG) findings are equivocal. In decades past, nerve biopsy was a key diagnostic tool for this evaluation.</p><p>Various imaging techniques are emerging as potential diagnostic modalities for neuromuscular diseases, including CMT. For example, nerve ultrasound can distinguish CMT1A from other subtypes [<a href="#rid208">208</a>]. (See  <a class="medical medical_review" href="/z/d/html/14145.html" rel="external">"Diagnostic ultrasound in neuromuscular disease", section on 'Findings in neuropathy'</a>.)</p><p class="headingAnchor" id="H1550567833"><span class="h2">When to suspect CMT</span><span class="headingEndMark"> — </span>Even in the absence of a clear family history of neuropathy, features that increase suspicion for an inherited neuropathy include [<a href="#rid47">47</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Slowly progressive symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Foot deformities (pes cavus and hammertoes)</p><p class="bulletIndent1"><span class="glyph">●</span>Lack of positive sensory symptoms despite clear sensory involvement</p><p></p><p>However, a key presenting feature, pes cavus, may also be present in isolation as an idiopathic, sometimes hereditary phenomenon. Therefore, it is important to examine a patient with pes cavus for other features of CMT before pursuing further diagnostic testing. A retrospective cohort study of children with pes cavus evaluated in a pediatric EMG laboratory found that the diagnosis of CMT correlated with the presence of one or more of the following [<a href="#rid209">209</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Weakness</p><p class="bulletIndent1"><span class="glyph">●</span>Distal muscle atrophy</p><p class="bulletIndent1"><span class="glyph">●</span>Gait abnormalities</p><p class="bulletIndent1"><span class="glyph">●</span>Sensory deficits</p><p class="bulletIndent1"><span class="glyph">●</span>Absent distal reflexes</p><p class="bulletIndent1"><span class="glyph">●</span>Family history of pes cavus and CMT</p><p></p><p>Thus, patients with several of these abnormalities should be referred for EMG, followed by genetic testing as indicated.</p><p>Patients with isolated pes cavus and none of the other clinical features associated with CMT should be monitored for the development of those features but do not require EMG and genetic testing.</p><p class="headingAnchor" id="H3491193063"><span class="h2">Electrodiagnostic studies</span><span class="headingEndMark"> — </span>EMG is the next step in the evaluation once a thorough history and physical examination have led the physician to suspect the presence of CMT. When performed by trained and experienced neurophysiologists, EMG is an efficient and highly informative diagnostic study that can confirm or disprove the presence of a polyneuropathy compatible with the diagnosis of CMT and determine the likely physiology of the neuropathy. For most patients with no family history of CMT, it is important to perform EMG prior to genetic testing, as the absence of a neuropathy would indicate that genetic testing for CMT is unnecessary, while the physiology of a neuropathy detected on EMG will help guide the interpretation of subsequent genetic testing.</p><p>In some situations, immediate genetic testing (rather than EMG) may be warranted, such as when the patient has an affected family member who already has a known CMT pathogenic variant or if CMT1A seems likely based upon the clinical features or family history. CMT1A is the most common type of CMT, and the genetic test is very simple and quick.</p><p>An EMG test typically involves two components, nerve conduction studies (NCS) and the needle EMG study; the latter is also referred to as the needle examination. The NCS portion of the test can detect signs of demyelination (via slow conduction velocities, prolonged distal latencies, prolonged F response latencies, conduction block, and/or temporal dispersion) and axonal loss (via low amplitude nerve potentials). However, low amplitude nerve potentials may be compatible with several different types of neuromuscular disease. Thus, these findings if present must be correlated with neurogenic abnormalities on the needle EMG examination to confirm the presence of an axonal neuropathy. In some cases, there will be features of both demyelination and axonal loss, which has been described in certain subtypes of CMT. In others, the EMG may be normal, indicating that CMT is not present, or may be abnormal, indicating that the disease process is not CMT but something entirely different, such as a myopathy or disorder of the neuromuscular junction.</p><p class="headingAnchor" id="H4005287849"><span class="h2">Genetic testing and counseling</span><span class="headingEndMark"> — </span>Genetic testing is a key component of the diagnostic evaluation for CMT and is necessary for the confirmation of subtype-specific diagnoses.</p><p>Genetic counseling should be made available to all patients and families with a suspected hereditary neuropathy [<a href="#rid47">47</a>]. Information about genetic testing and its implications should be provided. Prenatal testing for pregnancies at increased risk is possible for some types of CMT if the pathogenic variant in the family is already known [<a href="#rid210">210</a>].</p><p>Genetic screening for asymptomatic relatives of a patient diagnosed with CMT is an option, but risk assessment depends on several factors, including accuracy of the diagnosis, determination of the mode of inheritance for the individual family, and identification of a specific pathogenic variant in an affected relative by molecular genetic testing [<a href="#rid210">210</a>].</p><p class="headingAnchor" id="H3522945635"><span class="h3">Sanger and next-generation sequencing</span><span class="headingEndMark"> — </span>A landmark study published in 2011 clarified the genetic distribution of CMT subtypes [<a href="#rid7">7</a>]. This study examined 787 patients with a clinical diagnosis of CMT between 1997 and 2009, among whom specific pathogenic variants were identified in 67 percent. The most commonly identified CMT subtypes were CMT1A (<em>PMP22</em> duplication), CMTX1 (<em>GJB1</em> pathogenic variant), hereditary neuropathy with liability to pressure palsies (<em>PMP22</em> deletion), CMT1B (<em>MPZ</em> pathogenic variant), and CMT2A (<em>MFN2</em> pathogenic variant). Together, these five subtypes accounted for 92 percent of genetically defined CMT cases. All other CMT subtypes and associated pathogenic variants each accounted for &lt;1 percent of genetically defined CMT.</p><p>The take-home point of this study from the Sanger sequencing era was that genetic testing in most cases should focus only on <em>PMP22</em>, <em>MPZ</em>, <em>GJB1</em>, and <em>MFN2</em>, since these four genes were responsible for the vast majority of CMT cases. This prioritization of genes to be tested has become somewhat less relevant since 2011, as next-generation sequencing (NGS) test panels have reduced the cost dramatically.</p><p>In the era before NGS panels became widely available, broad genetic test panels based on the older Sanger sequencing technology were prohibitively expensive and included a large number of genes that were each associated with &lt;1 percent of cases [<a href="#rid211">211</a>]. With the advent of NGS, it is now only marginally more expensive to test 100 or more genes as it is to test a handful on one of these panels. However, both EMG and knowledge regarding the distribution of pathogenic variants remain important for the interpretation of genetic test results. The dreaded variant of unknown significance appears in NGS reports as often, if not more often, than in the old Sanger sequencing panels, and the ability to provide a clinical interpretation for such genetic test reports is a critical skill among physicians that is not adequately appreciated. The most common pathogenic variant of all, the <em>PMP22</em> duplication, is not detected reliably by short-read NGS technology, and thus it is important to know exactly what types of pathogenic variants will be identified with any genetic test that is ordered.</p><p class="headingAnchor" id="H554514096"><span class="h3">Focused genetic testing</span><span class="headingEndMark"> — </span>We have used an algorithmic strategy of focused genetic testing for CMT directed by age at onset, electrodiagnostic findings, and inheritance pattern [<a href="#rid7">7</a>]. Over time, this algorithm has become less relevant for the selection of diagnostic testing with the now widespread availability of next-generation sequencing panels that can be supplemented with deletion/duplication testing, but it still provides useful information with respect to the interpretation of genetic test results, especially when one or more variants of unknown significance are reported in a potentially causative gene.</p><p>The algorithm is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with slow upper extremity (ulnar) motor nerve conduction velocities (&gt;15 to ≤35 m/second) and a classic CMT phenotype (ie, walking before age 15 months), test first for the <em>PMP22</em> duplication (CMT1A). If negative and if no male-to-male transmission in the pedigree, test next for <em>GJB1</em> (CMTX1) followed by <em>MPZ</em> (CMT1B), or test only for <em>MPZ</em> if there is male-to-male transmission. If these are negative, test for single-nucleotide variants in <em>LITAF/SIMPLE</em> (CMT1C), <em>PMP22</em> (CMT1E), and <em>EGR2</em> (CMT1D). If these are all negative and if there is no affected parent or child, test for recessive forms of CMT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with very slow motor nerve conduction velocities (≤15 m/second) and delayed walking (age 15 months or later), test for both the <em>PMP22</em> duplication (CMT1A) and <em>MPZ</em> pathogenic variants (CMT1B). For patients who walked before age 15 months, test first for the <em>PMP22</em> duplication, followed by the <em>MPZ</em> pathogenic variant. If <em>PMP22</em> duplication and <em>MPZ</em> pathogenic variant testing are negative, test next for <em>PMP22</em> sequencing (CMT1E). If that is negative, proceed to testing for single-nucleotide variants in <em>LITAF/SIMPLE</em> (CMT1C), <em>PMP22</em>, and <em>EGR2</em> (CMT1D). If these all negative and if there is no affected parent or child, test for recessive forms of CMT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have intermediate slowing of motor nerve conduction velocities (&gt;35 to ≤45 m/second) with a classic CMT phenotype of childhood onset and no male-to-male transmission, test for <em>GJB1</em> (CMTX1) followed if negative by <em>MPZ</em> (CMT1B); if there is male-to-male transmission, test only for <em>MPZ</em>. If these are all negative and there is no affected parent or child, test for recessive forms of CMT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with intermediate slowing of motor nerve conduction velocities (&gt;35 to ≤45 m/second) and adult-onset CMT, test first for <em>MPZ</em> pathogenic variants (CMT1B). If negative and no male-to-male transmission, test next for <em>GJB1</em> (CMTX1); if there is male-to-male transmission and no affected parent or child, test for recessive forms of CMT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with either normal upper extremity motor nerve conduction velocities (&gt;45 m/second) or unobtainable motor nerve conduction velocities and compound muscle action potentials who have symptom onset in infancy or severe symptoms in childhood, first test for <em>MFN2</em> (CMT2A). For patients with a classic phenotype or adult onset and no male-to-male transmission, first test for <em>GJB1</em> (CMTX1) followed if negative by <em>MPZ</em> (CMT1B); if there is male-to-male transmission, test only for <em>MPZ</em>. If testing for <em>GJB1</em> and/or <em>MPZ</em> is negative, test next for <em>MFN2</em>. Regardless of age of onset or severity, testing for other forms of CMT2 may be appropriate if testing for CMT2A, CMTX1, and CMT1B is negative. For patients with pure motor upper limb greater than lower limb onset, test next for <em>GARS</em> (CMT2D); for other presentations, test for both <em>NEFL</em> (CMT2E) and <em>GDAP1</em> (CMT2K). If these are all negative and there is no affected parent or child, test for recessive forms of axonal CMT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary neuropathy with liability to pressure palsies (HNPP) is distinguished from other forms of CMT by a distinct phenotype that includes focal episodes of weakness or sensory loss (see <a class="local">'Hereditary neuropathy with liability to pressure palsy'</a> above). Electrophysiologic studies show a distinctive sensorimotor neuropathy pattern that can help to establish the diagnosis [<a href="#rid28">28,212</a>]. A generalized sensory neuropathy with slowed conduction velocity and prolongation of distal motor latencies occurs, the latter often including findings suggestive of carpal tunnel syndrome. Motor conduction velocity is slowed only mildly, and F-wave latencies are prolonged. These changes are indicative of disproportionate slowing of distal nerve conduction. A superimposed but independent entrapment neuropathy with focal slowing at sites of compression with acute weakness also occurs. When these features are present, test for <em>PMP22</em> deletion and single-nucleotide variants.</p><p></p><p class="headingAnchor" id="H1806655667"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of CMT includes a long list of other length-dependent neuropathies with hereditary etiologies as well as acquired peripheral neuropathies of various causes [<a href="#rid47">47,207,210</a>].</p><p class="headingAnchor" id="H3230559719"><span class="h2">Hereditary conditions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic pes cavus</strong> may cause some foot pain and gait difficulties and raises suspicion for CMT. However, this condition does not involve a detectable neuropathy. Electromyography (EMG) can help to differentiate the two possible diagnoses for a patient who presents with pes cavus but little or no other associated symptoms or signs of CMT. Genetic testing is not indicated if the EMG does not show the presence of a neuropathy [<a href="#rid209">209</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial amyloid polyneuropathy</strong> (FAP) represents a group of common autosomal dominant multisystemic disorders associated with polyneuropathy. Unlike CMT, FAP usually presents in later life with progressive pain and sensory loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Friedreich ataxia</strong> is an autosomal recessive disorder. Almost all patients present with limb and gait ataxia. Deep tendon reflexes eventually are lost in most patients. Additional manifestations can include optic atrophy, dysphagia, dysarthria, motor weakness, distal loss of position and vibration sense, reduced visual acuity, hearing loss, bladder dysfunction, kyphoscoliosis, cardiomyopathy, and diabetes mellitus. Atypical phenotypes include those with late-onset disease, preserved reflexes, lower limb spasticity, and/or absence of cardiomyopathy. (See  <a class="medical medical_review" href="/z/d/html/6224.html" rel="external">"Friedreich ataxia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refsum disease</strong> is an autosomal recessive disorder caused by pathogenic variants in either the <em>PHYH</em> gene, which accounts for approximately 90 percent of cases, or the <em>PEX7</em> gene. Symptom onset varies from infancy to middle age. Initial clinical features typically include deteriorating vision due to retinitis pigmentosa and anosmia. Sensorineural hearing loss, ataxia, peripheral polyneuropathy, ichthyosis, and cardiac conduction defects develop later. The neuropathy resembles demyelinating CMT due to the presence of pes cavus, progressive course, and demyelinating features [<a href="#rid207">207</a>]; nerve conduction studies often show a slowed conduction velocity. Cerebrospinal fluid analysis shows an elevated protein concentration without an increase in cells. (See  <a class="medical medical_review" href="/z/d/html/6147.html" rel="external">"Peroxisomal disorders", section on 'Refsum disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Krabbe disease</strong> is a rare autosomal recessive disorder caused by the deficiency of galactocerebrosidase. Most patients with Krabbe disease present with symptoms within the first six months of life; approximately 10 percent present later in life, including adulthood. A peripheral motor sensory neuropathy occurs in all patients, but the early-onset forms are dominated by symptoms related to central nervous system dysfunction, including irritability, developmental delay or regression, limb spasticity, axial hypotonia, absent reflexes, optic atrophy, and microcephaly. Seizures and tonic extensor spasms eventually appear. (See  <a class="medical medical_review" href="/z/d/html/6188.html" rel="external">"Krabbe disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metachromatic leukodystrophy</strong> (MLD) is an autosomal recessive lysosomal disease caused by pathogenic variants in the arylsulfatase A (<em>ARSA</em>) gene. Peripheral neuropathy occurs in all forms and may be a presenting feature, particularly in the late infantile form. The late-infantile form of MLD presents from age 6 months to 2 years; early signs include regression of motor skills, gait difficulty, ataxia, hypotonia, extensor plantar responses, optic atrophy, and peripheral neuropathy. The juvenile form of MLD presents between 3 and 16 years of age with gait disturbance, intellectual impairment, ataxia, upper motor neuron signs, and a peripheral neuropathy. Seizures may occur. (See  <a class="medical medical_review" href="/z/d/html/6195.html" rel="external">"Metachromatic leukodystrophy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ataxia-ocular apraxia type 1</strong> (AOA1) is an autosomal recessive disorder caused by pathogenic variants in the <em>APTX</em> gene. It is characterized by cerebellar ataxia, oculomotor apraxia, cerebellar atrophy, and a severe axonal sensorimotor neuropathy that can resemble CMT. Additional manifestations include hypoalbuminemia and elevation of serum total cholesterol. (See  <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">"Ataxia-telangiectasia", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adrenomyeloneuropathy</strong> (AMN) is a form of adrenoleukodystrophy, an X-linked disorder caused by pathogenic variants in the <em>ABCD1</em> gene. AMN typically presents in adult males between 20 and 40 years of age. The primary manifestation is spinal cord dysfunction with progressive spastic paraparesis, abnormal sphincter control, and sexual dysfunction. Gonadal dysfunction may precede motor abnormalities. The majority have adrenal insufficiency. AMN may also present as a progressive cerebellar disorder. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Myeloneuropathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distal hereditary motor neuropathies</strong> (dHMN) are a group of rare, genetically heterogeneous disorders characterized by slowly progressive distal motor weakness and length-dependent neuropathy [<a href="#rid47">47</a>]. They are distinguished from CMT by the absence of sensory involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biallelic pathogenic variants in </strong><strong><em>SORD</em></strong> cause an inherited predominantly motor neuropathy [<a href="#rid213">213</a>]. Affected individuals have been classified as having a dHMN or CMT2, depending on the individual case.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hereditary sensory and autonomic neuropathies</strong> (HSAN) occur much less frequently than CMT. The major feature of these conditions is loss of large myelinated and unmyelinated fibers. HSAN type I, the most common form, is characterized by degeneration of dorsal root ganglion and motor neurons, leading to distal sensory loss and later distal muscle wasting and weakness and variable neural deafness. Bone necrosis and spontaneous distal amputation can occur. Symptoms often begin in early childhood but may be delayed until the third decade. (See  <a class="medical medical_review" href="/z/d/html/6227.html" rel="external">"Hereditary sensory and autonomic neuropathies", section on 'HSAN1'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brown-Vialetto-van Laere disease</strong> is an autosomal recessive condition characterized by sensorineural deafness, cranial neuropathies including bulbar palsy, and signs of motor neuron disease. The associated gene is <em>SLC52A3</em>, previously known as <em>C20ORF54</em>, which encodes a <a class="drug drug_general" data-topicid="9861" href="/z/d/drug information/9861.html" rel="external">riboflavin</a> transporter [<a href="#rid214">214</a>]. Some affected individuals improve with riboflavin therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>A biotin-deficient autosomal recessive syndrome</strong> has been associated with biallelic variants in <em>SLC5A6</em> [<a href="#rid215">215</a>]. Patients may present with failure to thrive, developmental delay, and seizures. However, the phenotype in patients with milder symptoms includes a motor neuropathy that may respond to therapy with <a class="drug drug_general" data-topicid="120386" href="/z/d/drug information/120386.html" rel="external">biotin</a>, <a class="drug drug_general" data-topicid="10191" href="/z/d/drug information/10191.html" rel="external">pantothenic acid</a>, and lipoic acid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The distal muscular dystrophies</strong> are a heterogeneous group of rare genetic myopathies  (<a class="graphic graphic_table graphicRef51980" href="/z/d/graphic/51980.html" rel="external">table 2</a>) characterized by weakness that starts distally in the arms and/or legs and gradually progresses to affect proximal muscles. Almost all forms of distal myopathy can present as early as the second decade, although the onset is usually between 40 and 60 years of age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several mitochondrial disorders are associated with peripheral neuropathy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mitochondrial neurogastrointestinal encephalopathy</strong> (MNGIE) is a multisystem disorder characterized by progressive, severe gastrointestinal dysmotility and cachexia, ptosis, ophthalmoplegia or ophthalmoparesis, symmetric polyneuropathy, and asymptomatic leukoencephalopathy. The age of onset, the order of symptom presentation, and the rate of disease progression are highly variable.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neuropathy, ataxia, and retinitis pigmentosa</strong> (NARP) is characterized by a variable combination of developmental delay, sensory polyneuropathy, ataxia, pigmentary retinopathy, muscle weakness, epilepsy, and dementia. Late childhood or adult onset is most common.</p><p></p><p class="headingAnchor" id="H1155810377"><span class="h2">Acquired conditions</span><span class="headingEndMark"> — </span>Acquired peripheral neuropathy may be idiopathic or caused by systemic diseases (eg, diabetes mellitus, chronic HIV infection, hypothyroidism, vitamin deficiencies, neurosyphilis, and neuroborreliosis), inflammatory and immune-mediated mechanisms (eg, chronic inflammatory demyelinating polyneuropathy [CIDP], vasculitis, and occult neoplasm), and toxins (eg, alcohol, chemotherapy, and heavy metals).</p><p>Of these, the most important to recognize in the differential diagnosis of CMT are the immune-mediated neuropathies, particularly CIDP [<a href="#rid207">207</a>]. CIDP is a disorder of peripheral nerves and nerve roots with a number of variants. Both the cellular and humoral components of the immune system appear to be involved in the pathogenesis of CIDP and its variants. The classic form of CIDP is fairly symmetric and motor involvement is greater than sensory. Weakness is present in both proximal and distal muscles. Most patients have globally diminished or absent reflexes. The course may be progressive or relapsing-remitting. In some cases, CIDP may mimic CMT [<a href="#rid207">207</a>]. Nerve conduction studies in CIDP typically show nonuniform, nonhomogeneous slowing with partial or complete conduction blocks. This finding can help differentiate CIDP from CMT, since nerve conduction slowing in the demyelinating forms of CMT is typically diffuse and homogeneous. (See  <a class="medical medical_review" href="/z/d/html/5264.html" rel="external">"Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H781703"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Management of CMT is currently supportive; however, such supportive therapy can dramatically improve a patient's quality of life. Specific disease-modifying therapy is not available. This is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/113945.html" rel="external">"Charcot-Marie-Tooth disease: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H915366019"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116787.html" rel="external">"Society guideline links: Neuropathy"</a>.)</p><p class="headingAnchor" id="H14096322"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83812.html" rel="external">"Patient education: Charcot-Marie-Tooth disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19900458"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and shared features </strong>– Charcot-Marie-Tooth (CMT) disease is a spectrum of inherited disorders caused by pathogenic variants in genes that are expressed in peripheral nerve myelin and/or axons. Common features include both motor and sensory nerve manifestations with distal leg weakness, foot deformities (pes cavus, hammer toes), and sensory deficits  (<a class="graphic graphic_table graphicRef72688" href="/z/d/graphic/72688.html" rel="external">table 1</a>). (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis </strong>– A comprehensive history and physical examination remain the core for diagnosis and evaluation of CMT. Genetic testing is key to confirming the diagnosis after electrodiagnostic testing. (See <a class="local">'Evaluation and diagnosis'</a> above and <a class="local">'When to suspect CMT'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– The differential diagnosis of CMT includes several length-dependent neuropathies with hereditary etiologies as well as acquired peripheral neuropathies of various causes. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific CMT disorders</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CMT1 </strong>– CMT1 is a demyelinating disorder characterized by calf muscle atrophy, pes cavus foot deformity, hammer toes, and loss of reflexes. Affected patients typically present in the first or early second decade, but infants may be symptomatic. Sensory loss is gradual and mainly involves proprioception and vibration. Later changes include atrophy of the intrinsic hand and foot muscles. Palpable enlargement of the peripheral nerves may occur. Sural nerve biopsy shows "onion bulb" demyelination that affects primarily the large nerve fibers. (See <a class="local">'CMT1'</a> above.)</p><p></p><p class="bulletIndent2">The most common type of CMT1, CMT1A, is most frequently caused by a duplication of the <em>PMP22</em> gene. Hereditary neuropathy with liability to pressure palsy (HNPP), a recurrent, episodic demyelinating neuropathy, is an autosomal dominant disorder associated with <em>PMP22</em> deletions and single-nucleotide variants that is allelic to CMT1A. CMT1B is most often caused by single-nucleotide variants in the myelin protein zero (<em>MPZ</em>) gene. (See <a class="local">'Genetics of CMT1'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CMT2 </strong>– CMT2, also called axonal CMT, is characterized by predominating sensory loss along with distal weakness, atrophy, decreased deep tendon reflexes, and variable foot deformity. The onset of symptoms usually is in the second or third decade of life. The genetic basis of CMT2 is heterogeneous, though <em>MFN2</em> pathogenic variants appear to be the most common cause. (See <a class="local">'CMT2'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CMTX1 </strong>– CMTX1 is an X-linked dominant demyelinating and axonal disorder, characterized by gait impairment and foot deformities. Children and young adults with CMTX1 can experience transient stroke-like episodes. It is caused by pathogenic variants in the <em>GJB1 </em>or connexin 32 gene<em>.</em> (See <a class="local">'X-linked CMT'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CMT3 </strong>– Dejerine-Sottas syndrome and congenital hypomyelinating neuropathy, classified as CMT3, are severe, early-onset peripheral neuropathies that present in infancy with hypotonia. They are caused by several genetic variants including <em>PMP22</em>, <em>MPZ</em>, and <em>EGR2 </em>genes that lead to thin, poorly formed myelin. (See <a class="local">'CMT3'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CMT4 </strong>– CMT4 is a heterogeneous group of rare autosomal recessive demyelinating motor sensory neuropathies. Individuals with CMT4 have a typical CMT phenotype of distal muscle weakness and atrophy associated with sensory loss and foot deformities (eg, pes cavus). (See <a class="local">'CMT4'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intermediate CMT </strong>– Intermediate CMT is an uncommon variant characterized by both axonal and demyelinating clinical and histologic features that are "intermediate" between CMT1 (primarily demyelinating) and CMT2 (primarily axonal). (See <a class="local">'Intermediate CMT'</a> above.)</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges Robert P Cruse, DO, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Dyck PJ. Neuronal atrophy and degeneration predominantly affecting peripheral sensory and autonomic neurons. In: Peripheral Neuropathy, Dyck PJ, Thomas PK, Lambert EH, et al (Eds), WB Saunders, Philadelphia 1984. Vol 2.</li><li><a class="nounderline abstract_t">Murakami T, Sunada Y. Schwann Cell and the Pathogenesis of Charcot-Marie-Tooth Disease. Adv Exp Med Biol 2019; 1190:301.</a></li><li><a class="nounderline abstract_t">Lupski JR. Charcot-Marie-Tooth polyneuropathy: duplication, gene dosage, and genetic heterogeneity. Pediatr Res 1999; 45:159.</a></li><li><a class="nounderline abstract_t">Kamholz J, Menichella D, Jani A, et al. Charcot-Marie-Tooth disease type 1: molecular pathogenesis to gene therapy. Brain 2000; 123 ( Pt 2):222.</a></li><li><a class="nounderline abstract_t">Klein CJ, Duan X, Shy ME. Inherited neuropathies: clinical overview and update. Muscle Nerve 2013; 48:604.</a></li><li><a class="nounderline abstract_t">Pareyson D, Saveri P, Pisciotta C. New developments in Charcot-Marie-Tooth neuropathy and related diseases. Curr Opin Neurol 2017; 30:471.</a></li><li><a class="nounderline abstract_t">Saporta AS, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011; 69:22.</a></li><li><a class="nounderline abstract_t">Yoshimura A, Yuan JH, Hashiguchi A, et al. Genetic profile and onset features of 1005 patients with Charcot-Marie-Tooth disease in Japan. J Neurol Neurosurg Psychiatry 2019; 90:195.</a></li><li><a class="nounderline abstract_t">Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol 2013; 9:562.</a></li><li><a class="nounderline abstract_t">Barreto LC, Oliveira FS, Nunes PS, et al. Epidemiologic Study of Charcot-Marie-Tooth Disease: A Systematic Review. Neuroepidemiology 2016; 46:157.</a></li><li><a class="nounderline abstract_t">Mersiyanova IV, Ismailov SM, Polyakov AV, et al. Screening for mutations in the peripheral myelin genes PMP22, MPZ and Cx32 (GJB1) in Russian Charcot-Marie-Tooth neuropathy patients. Hum Mutat 2000; 15:340.</a></li><li><a class="nounderline abstract_t">Hoebeke C, Bonello-Palot N, Audic F, et al. Retrospective study of 75 children with peripheral inherited neuropathy: Genotype-phenotype correlations. Arch Pediatr 2018; 25:452.</a></li><li><a class="nounderline abstract_t">Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis. J Neurol Neurosurg Psychiatry 2015; 86:873.</a></li><li><a class="nounderline abstract_t">Roy EP 3rd, Gutmann L, Riggs JE. Longitudinal conduction studies in hereditary motor and sensory neuropathy type 1. Muscle Nerve 1989; 12:52.</a></li><li><a class="nounderline abstract_t">Rudnik-Schöneborn S, Röhrig D, Nicholson G, Zerres K. Pregnancy and delivery in Charcot-Marie-Tooth disease type 1. Neurology 1993; 43:2011.</a></li><li><a class="nounderline abstract_t">Hagberg B, Lyon G. Pooled European series of hereditary peripheral neuropathies in infancy and childhood. A "correspondence work shop" report of the European Federation of Child Neurology Societies (EFCNS). Neuropediatrics 1981; 12:9.</a></li><li><a class="nounderline abstract_t">Krajewski KM, Lewis RA, Fuerst DR, et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 2000; 123 ( Pt 7):1516.</a></li><li><a class="nounderline abstract_t">Videler AJ, van Dijk JP, Beelen A, et al. Motor axon loss is associated with hand dysfunction in Charcot-Marie-Tooth disease 1a. Neurology 2008; 71:1254.</a></li><li><a class="nounderline abstract_t">Gabreëls-Festen AA, Gabreëls FJ, Jennekens FG, et al. Autosomal recessive form of hereditary motor and sensory neuropathy type I. Neurology 1992; 42:1755.</a></li><li><a class="nounderline abstract_t">Hahn AF, Brown WF, Koopman WJ, Feasby TE. X-linked dominant hereditary motor and sensory neuropathy. Brain 1990; 113 ( Pt 5):1511.</a></li><li><a class="nounderline abstract_t">Bergoffen J, Trofatter J, Pericak-Vance MA, et al. Linkage localization of X-linked Charcot-Marie-Tooth disease. Am J Hum Genet 1993; 52:312.</a></li><li><a class="nounderline abstract_t">Bergoffen J, Scherer SS, Wang S, et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993; 262:2039.</a></li><li><a class="nounderline abstract_t">Shaffer LG, Kennedy GM, Spikes AS, Lupski JR. Diagnosis of CMT1A duplications and HNPP deletions by interphase FISH: implications for testing in the cytogenetics laboratory. Am J Med Genet 1997; 69:325.</a></li><li><a class="nounderline abstract_t">Hanemann CO, D'Urso D, Gabreëls-Festen AA, Müller HW. Mutation-dependent alteration in cellular distribution of peripheral myelin protein 22 in nerve biopsies from Charcot-Marie-Tooth type 1A. Brain 2000; 123 ( Pt 5):1001.</a></li><li><a class="nounderline abstract_t">Dematteis M, Pépin JL, Jeanmart M, et al. Charcot-Marie-Tooth disease and sleep apnoea syndrome: a family study. Lancet 2001; 357:267.</a></li><li><a class="nounderline abstract_t">Dziewas R, Waldmann N, Böntert M, et al. Increased prevalence of obstructive sleep apnoea in patients with Charcot-Marie-Tooth disease: a case control study. J Neurol Neurosurg Psychiatry 2008; 79:829.</a></li><li><a class="nounderline abstract_t">Gabreëls-Festen AA, Gabreëls FJ, Joosten EM, et al. Hereditary neuropathy with liability to pressure palsies in childhood. Neuropediatrics 1992; 23:138.</a></li><li><a class="nounderline abstract_t">Mouton P, Tardieu S, Gouider R, et al. Spectrum of clinical and electrophysiologic features in HNPP patients with the 17p11.2 deletion. Neurology 1999; 52:1440.</a></li><li><a class="nounderline abstract_t">Potulska-Chromik A, Sinkiewicz-Darol E, Ryniewicz B, et al. Clinical, electrophysiological, and molecular findings in early onset hereditary neuropathy with liability to pressure palsy. Muscle Nerve 2014; 50:914.</a></li><li><a class="nounderline abstract_t">Korn-Lubetzki I, Argov Z, Raas-Rothschild A, et al. Family with inflammatory demyelinating polyneuropathy and the HNPP 17p12 deletion. Am J Med Genet 2002; 113:275.</a></li><li><a class="nounderline abstract_t">Luigetti M, Del Grande A, Conte A, et al. Clinical, neurophysiological and pathological findings of HNPP patients with 17p12 deletion: a single-centre experience. J Neurol Sci 2014; 341:46.</a></li><li><a class="nounderline abstract_t">Yilmaz U, Bird TT, Carter GT, et al. Pain in hereditary neuropathy with liability to pressure palsy: an association with fibromyalgia syndrome? Muscle Nerve 2015; 51:385.</a></li><li><a class="nounderline abstract_t">Choi YH, Dunn B. Low back pain with radicular symptoms as a presentation of hereditary neuropathy with liability to pressure palsies: the diagnostic challenge of an atypical presentation. Muscle Nerve 2016; 53:655.</a></li><li><a class="nounderline abstract_t">Sanahuja J, Franco E, Rojas-García R, et al. Central nervous system involvement in hereditary neuropathy with liability to pressure palsies: description of a large family with this association. Arch Neurol 2005; 62:1911.</a></li><li><a class="nounderline abstract_t">Tackenberg B, Möller JC, Rindock H, et al. CNS involvement in hereditary neuropathy with pressure palsies (HNPP). Neurology 2006; 67:2250.</a></li><li><a class="nounderline abstract_t">Meier C, Moll C. Hereditary neuropathy with liability to pressure palsies. Report of two families and review of the literature. J Neurol 1982; 228:73.</a></li><li><a class="nounderline abstract_t">Stögbauer F, Young P, Kuhlenbäumer G, et al. Hereditary recurrent focal neuropathies: clinical and molecular features. Neurology 2000; 54:546.</a></li><li><a class="nounderline abstract_t">Mariman EC, Gabreëls-Festen AA, van Beersum SE, et al. Prevalence of the 1.5-Mb 17p deletion in families with hereditary neuropathy with liability to pressure palsies. Ann Neurol 1994; 36:650.</a></li><li class="breakAll">Bird TD. Hereditary neuropathy with liability to pressure palsies. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1392/ (Accessed on December 07, 2011).</li><li><a class="nounderline abstract_t">Li J, Ghandour K, Radovanovic D, et al. Stoichiometric alteration of PMP22 protein determines the phenotype of hereditary neuropathy with liability to pressure palsies. Arch Neurol 2007; 64:974.</a></li><li><a class="nounderline abstract_t">Infante J, García A, Combarros O, et al. Diagnostic strategy for familial and sporadic cases of neuropathy associated with 17p11.2 deletion. Muscle Nerve 2001; 24:1149.</a></li><li><a class="nounderline abstract_t">Guo J, Wang L, Zhang Y, et al. Abnormal junctions and permeability of myelin in PMP22-deficient nerves. Ann Neurol 2014; 75:255.</a></li><li><a class="nounderline abstract_t">Robert-Varvat F, Jousserand G, Bouhour F, et al. Hereditary neuropathy with liability to pressure palsy in patients under 30 years old: Neurophysiological data and proposed electrodiagnostic criteria. Muscle Nerve 2018; 57:217.</a></li><li><a class="nounderline abstract_t">Bird TD. Historical perspective of defining Charcot-Marie-Tooth type 1B. Ann N Y Acad Sci 1999; 883:6.</a></li><li><a class="nounderline abstract_t">Hayasaka K, Himoro M, Sato W, et al. Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene. Nat Genet 1993; 5:31.</a></li><li><a class="nounderline abstract_t">Hattori N, Yamamoto M, Yoshihara T, et al. Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients. Brain 2003; 126:134.</a></li><li><a class="nounderline abstract_t">Saporta MA. Charcot-Marie-Tooth disease and other inherited neuropathies. Continuum (Minneap Minn) 2014; 20:1208.</a></li><li><a class="nounderline abstract_t">Shy ME, Jáni A, Krajewski K, et al. Phenotypic clustering in MPZ mutations. Brain 2004; 127:371.</a></li><li><a class="nounderline abstract_t">Mastaglia FL, Nowak KJ, Stell R, et al. Novel mutation in the myelin protein zero gene in a family with intermediate hereditary motor and sensory neuropathy. J Neurol Neurosurg Psychiatry 1999; 67:174.</a></li><li><a class="nounderline abstract_t">Banchs I, Casasnovas C, Montero J, et al. Charcot-Marie-Tooth disease with intermediate conduction velocities caused by a novel mutation in the MPZ gene. Muscle Nerve 2010; 42:184.</a></li><li><a class="nounderline abstract_t">Wrabetz L, Feltri ML, Quattrini A, et al. P(0) glycoprotein overexpression causes congenital hypomyelination of peripheral nerves. J Cell Biol 2000; 148:1021.</a></li><li><a class="nounderline abstract_t">Tyson J, Ellis D, Fairbrother U, et al. Hereditary demyelinating neuropathy of infancy. A genetically complex syndrome. Brain 1997; 120 ( Pt 1):47.</a></li><li><a class="nounderline abstract_t">Maeda MH, Mitsui J, Soong BW, et al. Increased gene dosage of myelin protein zero causes Charcot-Marie-Tooth disease. Ann Neurol 2012; 71:84.</a></li><li><a class="nounderline abstract_t">Sabet A, Li J, Ghandour K, et al. Skin biopsies demonstrate MPZ splicing abnormalities in Charcot-Marie-Tooth neuropathy 1B. Neurology 2006; 67:1141.</a></li><li><a class="nounderline abstract_t">Spiryda LB. Myelin protein zero and membrane adhesion. J Neurosci Res 1998; 54:137.</a></li><li><a class="nounderline abstract_t">Matsuyama W, Nakagawa M, Takashima H, Osame M. Altered trafficking and adhesion function of MPZ mutations and phenotypes of Charcot-Marie-Tooth disease 1B. Acta Neuropathol 2002; 103:501.</a></li><li><a class="nounderline abstract_t">Lee YC, Yu CT, Lin KP, et al. MPZ mutation G123S characterization: evidence for a complex pathogenesis in CMT disease. Neurology 2008; 70:273.</a></li><li><a class="nounderline abstract_t">Street VA, Goldy JD, Golden AS, et al. Mapping of Charcot-Marie-Tooth disease type 1C to chromosome 16p identifies a novel locus for demyelinating neuropathies. Am J Hum Genet 2002; 70:244.</a></li><li><a class="nounderline abstract_t">Street VA, Bennett CL, Goldy JD, et al. Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology 2003; 60:22.</a></li><li><a class="nounderline abstract_t">Warner LE, Mancias P, Butler IJ, et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 1998; 18:382.</a></li><li><a class="nounderline abstract_t">Kousseff BG, Hadro TA, Treiber DL, et al. Charcot-Marie-Tooth disease with sensorineural hearing loss--an autosomal dominant trait. Birth Defects Orig Artic Ser 1982; 18:223.</a></li><li><a class="nounderline abstract_t">Kovach MJ, Lin JP, Boyadjiev S, et al. A unique point mutation in the PMP22 gene is associated with Charcot-Marie-Tooth disease and deafness. Am J Hum Genet 1999; 64:1580.</a></li><li><a class="nounderline abstract_t">Jordanova A, De Jonghe P, Boerkoel CF, et al. Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. Brain 2003; 126:590.</a></li><li><a class="nounderline abstract_t">Planté-Bordeneuve V, Guiochon-Mantel A, Lacroix C, et al. The Roussy-Lévy family: from the original description to the gene. Ann Neurol 1999; 46:770.</a></li><li><a class="nounderline abstract_t">Auer-Grumbach M, Strasser-Fuchs S, Wagner K, et al. Roussy-Lévy syndrome is a phenotypic variant of Charcot-Marie-Tooth syndrome IA associated with a duplication on chromosome 17p11.2. J Neurol Sci 1998; 154:72.</a></li><li><a class="nounderline abstract_t">Keller MP, Chance PF. Inherited peripheral neuropathy. Semin Neurol 1999; 19:353.</a></li><li><a class="nounderline abstract_t">Reilly MM. Axonal Charcot-Marie-Tooth disease: the fog is slowly lifting! Neurology 2005; 65:186.</a></li><li><a class="nounderline abstract_t">Bennett CL, Lawson VH, Brickell KL, et al. Late-onset hereditary axonal neuropathies. Neurology 2008; 71:14.</a></li><li><a class="nounderline abstract_t">Bouhouche A, Benomar A, Birouk N, et al. A locus for an axonal form of autosomal recessive Charcot-Marie-Tooth disease maps to chromosome 1q21.2-q21.3. Am J Hum Genet 1999; 65:722.</a></li><li><a class="nounderline abstract_t">Bouhouche A, Birouk N, Azzedine H, et al. Autosomal recessive axonal Charcot-Marie-Tooth disease (ARCMT2): phenotype-genotype correlations in 13 Moroccan families. Brain 2007; 130:1062.</a></li><li><a class="nounderline abstract_t">Ouvrier R, Geevasingha N, Ryan MM. Autosomal-recessive and X-linked forms of hereditary motor and sensory neuropathy in childhood. Muscle Nerve 2007; 36:131.</a></li><li><a class="nounderline abstract_t">Murphy SM, Laura M, Fawcett K, et al. Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry 2012; 83:706.</a></li><li><a class="nounderline abstract_t">Ouvrier R, Grew S. Mechanisms of disease and clinical features of mutations of the gene for mitofusin 2: an important cause of hereditary peripheral neuropathy with striking clinical variability in children and adults. Dev Med Child Neurol 2010; 52:328.</a></li><li><a class="nounderline abstract_t">Züchner S, Mersiyanova IV, Muglia M, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004; 36:449.</a></li><li><a class="nounderline abstract_t">Lawson VH, Graham BV, Flanigan KM. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology 2005; 65:197.</a></li><li><a class="nounderline abstract_t">Feely SM, Laura M, Siskind CE, et al. MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology 2011; 76:1690.</a></li><li><a class="nounderline abstract_t">Polke JM, Laurá M, Pareyson D, et al. Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations. Neurology 2011; 77:168.</a></li><li><a class="nounderline abstract_t">Carr AS, Polke JM, Wilson J, et al. MFN2 deletion of exons 7 and 8: founder mutation in the UK population. J Peripher Nerv Syst 2015; 20:67.</a></li><li><a class="nounderline abstract_t">Zhao C, Takita J, Tanaka Y, et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell 2001; 105:587.</a></li><li><a class="nounderline abstract_t">Bissar-Tadmouri N, Nelis E, Züchner S, et al. Absence of KIF1B mutation in a large Turkish CMT2A family suggests involvement of a second gene. Neurology 2004; 62:1522.</a></li><li><a class="nounderline abstract_t">Elliott JL, Kwon JM, Goodfellow PJ, Yee WC. Hereditary motor and sensory neuropathy IIB: clinical and electrodiagnostic characteristics. Neurology 1997; 48:23.</a></li><li><a class="nounderline abstract_t">Verhoeven K, De Jonghe P, Coen K, et al. Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet 2003; 72:722.</a></li><li><a class="nounderline abstract_t">Klein CJ, Cunningham JM, Atkinson EJ, et al. The gene for HMSN2C maps to 12q23-24: a region of neuromuscular disorders. Neurology 2003; 60:1151.</a></li><li><a class="nounderline abstract_t">McEntagart ME, Reid SL, Irrthum A, et al. Confirmation of a hereditary motor and sensory neuropathy IIC locus at chromosome 12q23-q24. Ann Neurol 2005; 57:293.</a></li><li><a class="nounderline abstract_t">Auer-Grumbach M, Olschewski A, Papić L, et al. Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat Genet 2010; 42:160.</a></li><li><a class="nounderline abstract_t">Chen DH, Sul Y, Weiss M, et al. CMT2C with vocal cord paresis associated with short stature and mutations in the TRPV4 gene. Neurology 2010; 75:1968.</a></li><li><a class="nounderline abstract_t">Ionasescu V, Searby C, Sheffield VC, et al. Autosomal dominant Charcot-Marie-Tooth axonal neuropathy mapped on chromosome 7p (CMT2D). Hum Mol Genet 1996; 5:1373.</a></li><li><a class="nounderline abstract_t">Antonellis A, Ellsworth RE, Sambuughin N, et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet 2003; 72:1293.</a></li><li><a class="nounderline abstract_t">Mersiyanova IV, Perepelov AV, Polyakov AV, et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 2000; 67:37.</a></li><li><a class="nounderline abstract_t">De Jonghe P, Mersivanova I, Nelis E, et al. Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E. Ann Neurol 2001; 49:245.</a></li><li><a class="nounderline abstract_t">Yum SW, Zhang J, Mo K, et al. A novel recessive Nefl mutation causes a severe, early-onset axonal neuropathy. Ann Neurol 2009; 66:759.</a></li><li><a class="nounderline abstract_t">Fabrizi GM, Cavallaro T, Angiari C, et al. Charcot-Marie-Tooth disease type 2E, a disorder of the cytoskeleton. Brain 2007; 130:394.</a></li><li><a class="nounderline abstract_t">Ismailov SM, Fedotov VP, Dadali EL, et al. A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2F) maps to chromosome 7q11-q21. Eur J Hum Genet 2001; 9:646.</a></li><li><a class="nounderline abstract_t">Evgrafov OV, Mersiyanova I, Irobi J, et al. Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat Genet 2004; 36:602.</a></li><li><a class="nounderline abstract_t">Senderek J, Hermanns B, Lehmann U, et al. Charcot-Marie-Tooth neuropathy type 2 and P0 point mutations: two novel amino acid substitutions (Asp61Gly; Tyr119Cys) and a possible "hotspot" on Thr124Met. Brain Pathol 2000; 10:235.</a></li><li><a class="nounderline abstract_t">Chapon F, Latour P, Diraison P, et al. Axonal phenotype of Charcot-Marie-Tooth disease associated with a mutation in the myelin protein zero gene. J Neurol Neurosurg Psychiatry 1999; 66:779.</a></li><li><a class="nounderline abstract_t">De Jonghe P, Timmerman V, Ceuterick C, et al. The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype. Brain 1999; 122 ( Pt 2):281.</a></li><li><a class="nounderline abstract_t">Misu K, Yoshihara T, Shikama Y, et al. An axonal form of Charcot-Marie-Tooth disease showing distinctive features in association with mutations in the peripheral myelin protein zero gene (Thr124Met or Asp75Val). J Neurol Neurosurg Psychiatry 2000; 69:806.</a></li><li><a class="nounderline abstract_t">Birouk N, Azzedine H, Dubourg O, et al. Phenotypical features of a Moroccan family with autosomal recessive Charcot-Marie-Tooth disease associated with the S194X mutation in the GDAP1 gene. Arch Neurol 2003; 60:598.</a></li><li><a class="nounderline abstract_t">Chung KW, Kim SM, Sunwoo IN, et al. A novel GDAP1 Q218E mutation in autosomal dominant Charcot-Marie-Tooth disease. J Hum Genet 2008; 53:360.</a></li><li><a class="nounderline abstract_t">Crimella C, Tonelli A, Airoldi G, et al. The GST domain of GDAP1 is a frequent target of mutations in the dominant form of axonal Charcot Marie Tooth type 2K. J Med Genet 2010; 47:712.</a></li><li><a class="nounderline abstract_t">Tang BS, Luo W, Xia K, et al. A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2L) maps to chromosome 12q24. Hum Genet 2004; 114:527.</a></li><li><a class="nounderline abstract_t">Irobi J, Van Impe K, Seeman P, et al. Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nat Genet 2004; 36:597.</a></li><li><a class="nounderline abstract_t">Fabrizi GM, Ferrarini M, Cavallaro T, et al. Two novel mutations in dynamin-2 cause axonal Charcot-Marie-Tooth disease. Neurology 2007; 69:291.</a></li><li><a class="nounderline abstract_t">Gallardo E, Claeys KG, Nelis E, et al. Magnetic resonance imaging findings of leg musculature in Charcot-Marie-Tooth disease type 2 due to dynamin 2 mutation. J Neurol 2008; 255:986.</a></li><li><a class="nounderline abstract_t">Kennerson ML, Zhu D, Gardner RJ, et al. Dominant intermediate Charcot-Marie-Tooth neuropathy maps to chromosome 19p12-p13.2. Am J Hum Genet 2001; 69:883.</a></li><li><a class="nounderline abstract_t">Züchner S, Noureddine M, Kennerson M, et al. Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease. Nat Genet 2005; 37:289.</a></li><li><a class="nounderline abstract_t">Nelis E, Berciano J, Verpoorten N, et al. Autosomal dominant axonal Charcot-Marie-Tooth disease type 2 (CMT2G) maps to chromosome 12q12-q13.3. J Med Genet 2004; 41:193.</a></li><li><a class="nounderline abstract_t">Peeters K, Palaima P, Pelayo-Negro AL, et al. Charcot-Marie-Tooth disease type 2G redefined by a novel mutation in LRSAM1. Ann Neurol 2016; 80:823.</a></li><li><a class="nounderline abstract_t">Cottenie E, Kochanski A, Jordanova A, et al. Truncating and missense mutations in IGHMBP2 cause Charcot-Marie Tooth disease type 2. Am J Hum Genet 2014; 95:590.</a></li><li><a class="nounderline abstract_t">Shi CH, Song B, Luo HY, et al. Recessive hereditary motor and sensory neuropathy caused by IGHMBP2 gene mutation. Neurology 2015; 85:383.</a></li><li><a class="nounderline abstract_t">Higuchi Y, Hashiguchi A, Yuan J, et al. Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth disease type 2. Ann Neurol 2016; 79:659.</a></li><li><a class="nounderline abstract_t">Lupo V, Frasquet M, Sánchez-Monteagudo A, et al. Characterising the phenotype and mode of inheritance of patients with inherited peripheral neuropathies carrying MME mutations. J Med Genet 2018; 55:814.</a></li><li><a class="nounderline abstract_t">Pitceathly RD, Murphy SM, Cottenie E, et al. Genetic dysfunction of MT-ATP6 causes axonal Charcot-Marie-Tooth disease. Neurology 2012; 79:1145.</a></li><li><a class="nounderline abstract_t">Lassuthova P, Rebelo AP, Ravenscroft G, et al. Mutations in ATP1A1 Cause Dominant Charcot-Marie-Tooth Type 2. Am J Hum Genet 2018; 102:505.</a></li><li><a class="nounderline abstract_t">Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol 2009; 8:654.</a></li><li><a class="nounderline abstract_t">Boerkoel CF, Takashima H, Lupski JR. The genetic convergence of Charcot-Marie-Tooth disease types 1 and 2 and the role of genetics in sporadic neuropathy. Curr Neurol Neurosci Rep 2002; 2:70.</a></li><li><a class="nounderline abstract_t">Huttner IG, Kennerson ML, Reddel SW, et al. Proof of genetic heterogeneity in X-linked Charcot-Marie-Tooth disease. Neurology 2006; 67:2016.</a></li><li><a class="nounderline abstract_t">Latour P, Lévy N, Paret M, et al. Mutations in the X-linked form of Charcot-Marie-Tooth disease in the French population. Neurogenetics 1997; 1:117.</a></li><li><a class="nounderline abstract_t">Shy ME, Siskind C, Swan ER, et al. CMT1X phenotypes represent loss of GJB1 gene function. Neurology 2007; 68:849.</a></li><li><a class="nounderline abstract_t">Yuan JH, Sakiyama Y, Hashiguchi A, et al. Genetic and phenotypic profile of 112 patients with X-linked Charcot-Marie-Tooth disease type 1. Eur J Neurol 2018; 25:1454.</a></li><li><a class="nounderline abstract_t">Yiu EM, Geevasinga N, Nicholson GA, et al. A retrospective review of X-linked Charcot-Marie-Tooth disease in childhood. Neurology 2011; 76:461.</a></li><li><a class="nounderline abstract_t">Al-Mateen M, Craig AK, Chance PF. The central nervous system phenotype of X-linked Charcot-Marie-Tooth disease: a transient disorder of children and young adults. J Child Neurol 2014; 29:342.</a></li><li><a class="nounderline abstract_t">Basu A, Horvath R, Esisi B, et al. Recurrent stroke-like episodes in X-linked Charcot-Marie-Tooth disease. Neurology 2011; 77:1205.</a></li><li><a class="nounderline abstract_t">Paulson HL, Garbern JY, Hoban TF, et al. Transient central nervous system white matter abnormality in X-linked Charcot-Marie-Tooth disease. Ann Neurol 2002; 52:429.</a></li><li><a class="nounderline abstract_t">Taylor RA, Simon EM, Marks HG, Scherer SS. The CNS phenotype of X-linked Charcot-Marie-Tooth disease: more than a peripheral problem. Neurology 2003; 61:1475.</a></li><li><a class="nounderline abstract_t">Koutsis G, Breza M, Velonakis G, et al. X linked Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence for an association. J Neurol Neurosurg Psychiatry 2019; 90:187.</a></li><li><a class="nounderline abstract_t">Nicholson G, Nash J. Intermediate nerve conduction velocities define X-linked Charcot-Marie-Tooth neuropathy families. Neurology 1993; 43:2558.</a></li><li><a class="nounderline abstract_t">Ionasescu VV, Trofatter J, Haines JL, et al. Heterogeneity in X-linked recessive Charcot-Marie-Tooth neuropathy. Am J Hum Genet 1991; 48:1075.</a></li><li><a class="nounderline abstract_t">Ionasescu VV, Trofatter J, Haines JL, et al. X-linked recessive Charcot-Marie-Tooth neuropathy: clinical and genetic study. Muscle Nerve 1992; 15:368.</a></li><li><a class="nounderline abstract_t">Wang Y, Yin F. A Review of X-linked Charcot-Marie-Tooth Disease. J Child Neurol 2016; 31:761.</a></li><li><a class="nounderline abstract_t">Brewer MH, Chaudhry R, Qi J, et al. Whole Genome Sequencing Identifies a 78 kb Insertion from Chromosome 8 as the Cause of Charcot-Marie-Tooth Neuropathy CMTX3. PLoS Genet 2016; 12:e1006177.</a></li><li><a class="nounderline abstract_t">Kanhangad M, Cornett K, Brewer MH, et al. Unique clinical and neurophysiologic profile of a cohort of children with CMTX3. Neurology 2018; 90:e1706.</a></li><li><a class="nounderline abstract_t">Cowchock FS, Duckett SW, Streletz LJ, et al. X-linked motor-sensory neuropathy type-II with deafness and mental retardation: a new disorder. Am J Med Genet 1985; 20:307.</a></li><li><a class="nounderline abstract_t">Rinaldi C, Grunseich C, Sevrioukova IF, et al. Cowchock syndrome is associated with a mutation in apoptosis-inducing factor. Am J Hum Genet 2012; 91:1095.</a></li><li><a class="nounderline abstract_t">Kim HJ, Hong SH, Ki CS, et al. A novel locus for X-linked recessive CMT with deafness and optic neuropathy maps to Xq21.32-q24. Neurology 2005; 64:1964.</a></li><li><a class="nounderline abstract_t">Kim HJ, Sohn KM, Shy ME, et al. Mutations in PRPS1, which encodes the phosphoribosyl pyrophosphate synthetase enzyme critical for nucleotide biosynthesis, cause hereditary peripheral neuropathy with hearing loss and optic neuropathy (cmtx5). Am J Hum Genet 2007; 81:552.</a></li><li><a class="nounderline abstract_t">Kennerson ML, Yiu EM, Chuang DT, et al. A new locus for X-linked dominant Charcot-Marie-Tooth disease (CMTX6) is caused by mutations in the pyruvate dehydrogenase kinase isoenzyme 3 (PDK3) gene. Hum Mol Genet 2013; 22:1404.</a></li><li><a class="nounderline abstract_t">Ouvrier RA, McLeod JG, Conchin TE. The hypertrophic forms of hereditary motor and sensory neuropathy. A study of hypertrophic Charcot-Marie-Tooth disease (HMSN type I) and Dejerine-Sottas disease (HMSN type III) in childhood. Brain 1987; 110 ( Pt 1):121.</a></li><li><a class="nounderline abstract_t">Parman Y, Battaloglu E, Baris I, et al. Clinicopathological and genetic study of early-onset demyelinating neuropathy. Brain 2004; 127:2540.</a></li><li><a class="nounderline abstract_t">Parman Y, Planté-Bordeneuve V, Guiochon-Mantel A, et al. Recessive inheritance of a new point mutation of the PMP22 gene in Dejerine-Sottas disease. Ann Neurol 1999; 45:518.</a></li><li><a class="nounderline abstract_t">Ikegami T, Ikeda H, Aoyama M, et al. Novel mutations of the peripheral myelin protein 22 gene in two pedigrees with Dejerine-Sottas disease. Hum Genet 1998; 102:294.</a></li><li><a class="nounderline abstract_t">Timmerman V, De Jonghe P, Ceuterick C, et al. Novel missense mutation in the early growth response 2 gene associated with Dejerine-Sottas syndrome phenotype. Neurology 1999; 52:1827.</a></li><li><a class="nounderline abstract_t">Boerkoel CF, Takashima H, Bacino CA, et al. EGR2 mutation R359W causes a spectrum of Dejerine-Sottas neuropathy. Neurogenetics 2001; 3:153.</a></li><li><a class="nounderline abstract_t">Boerkoel CF, Takashima H, Stankiewicz P, et al. Periaxin mutations cause recessive Dejerine-Sottas neuropathy. Am J Hum Genet 2001; 68:325.</a></li><li><a class="nounderline abstract_t">Charnas L, Trapp B, Griffin J. Congenital absence of peripheral myelin: abnormal Schwann cell development causes lethal arthrogryposis multiplex congenita. Neurology 1988; 38:966.</a></li><li><a class="nounderline abstract_t">Ghamdi M, Armstrong DL, Miller G. Congenital hypomyelinating neuropathy: a reversible case. Pediatr Neurol 1997; 16:71.</a></li><li><a class="nounderline abstract_t">Levy BK, Fenton GA, Loaiza S, Hayat GR. Unexpected recovery in a newborn with severe hypomyelinating neuropathy. Pediatr Neurol 1997; 16:245.</a></li><li><a class="nounderline abstract_t">Phillips JP, Warner LE, Lupski JR, Garg BP. Congenital hypomyelinating neuropathy: two patients with long-term follow-up. Pediatr Neurol 1999; 20:226.</a></li><li><a class="nounderline abstract_t">Mandich P, Mancardi GL, Varese A, et al. Congenital hypomyelination due to myelin protein zero Q215X mutation. Ann Neurol 1999; 45:676.</a></li><li><a class="nounderline abstract_t">Kochanski A, Drac H, Kabzińska D, et al. A novel MPZ gene mutation in congenital neuropathy with hypomyelination. Neurology 2004; 62:2122.</a></li><li><a class="nounderline abstract_t">McMillan HJ, Santagata S, Shapiro F, et al. Novel MPZ mutations and congenital hypomyelinating neuropathy. Neuromuscul Disord 2010; 20:725.</a></li><li><a class="nounderline abstract_t">Bolino A, Lonie LJ, Zimmer M, et al. Denaturing high-performance liquid chromatography of the myotubularin-related 2 gene (MTMR2) in unrelated patients with Charcot-Marie-Tooth disease suggests a low frequency of mutation in inherited neuropathy. Neurogenetics 2001; 3:107.</a></li><li class="breakAll">Bird TD. Charcot-Marie-Tooth neuropathy type 4. Gene Reviews. https://www.ncbi.nlm.nih.gov/books/NBK1468/ (Accessed on July 13, 2017).</li><li><a class="nounderline abstract_t">Ben Othmane K, Hentati F, Lennon F, et al. Linkage of a locus (CMT4A) for autosomal recessive Charcot-Marie-Tooth disease to chromosome 8q. Hum Mol Genet 1993; 2:1625.</a></li><li><a class="nounderline abstract_t">Baxter RV, Ben Othmane K, Rochelle JM, et al. Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nat Genet 2002; 30:21.</a></li><li><a class="nounderline abstract_t">Cuesta A, Pedrola L, Sevilla T, et al. The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. Nat Genet 2002; 30:22.</a></li><li><a class="nounderline abstract_t">Pedrola L, Espert A, Wu X, et al. GDAP1, the protein causing Charcot-Marie-Tooth disease type 4A, is expressed in neurons and is associated with mitochondria. Hum Mol Genet 2005; 14:1087.</a></li><li><a class="nounderline abstract_t">Senderek J, Bergmann C, Ramaekers VT, et al. Mutations in the ganglioside-induced differentiation-associated protein-1 (GDAP1) gene in intermediate type autosomal recessive Charcot-Marie-Tooth neuropathy. Brain 2003; 126:642.</a></li><li><a class="nounderline abstract_t">Chung KW, Hyun YS, Lee HJ, et al. Two recessive intermediate Charcot-Marie-Tooth patients with GDAP1 mutations. J Peripher Nerv Syst 2011; 16:143.</a></li><li><a class="nounderline abstract_t">Bolino A, Brancolini V, Bono F, et al. Localization of a gene responsible for autosomal recessive demyelinating neuropathy with focally folded myelin sheaths to chromosome 11q23 by homozygosity mapping and haplotype sharing. Hum Mol Genet 1996; 5:1051.</a></li><li><a class="nounderline abstract_t">Bolino A, Levy ER, Muglia M, et al. Genetic refinement and physical mapping of the CMT4B gene on chromosome 11q22. Genomics 2000; 63:271.</a></li><li><a class="nounderline abstract_t">Quattrone A, Gambardella A, Bono F, et al. Autosomal recessive hereditary motor and sensory neuropathy with focally folded myelin sheaths: clinical, electrophysiologic, and genetic aspects of a large family. Neurology 1996; 46:1318.</a></li><li><a class="nounderline abstract_t">Bolino A, Muglia M, Conforti FL, et al. Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat Genet 2000; 25:17.</a></li><li><a class="nounderline abstract_t">Pareyson D, Stojkovic T, Reilly MM, et al. A multicenter retrospective study of charcot-marie-tooth disease type 4B (CMT4B) associated with mutations in myotubularin-related proteins (MTMRs). Ann Neurol 2019; 86:55.</a></li><li><a class="nounderline abstract_t">Othmane KB, Johnson E, Menold M, et al. Identification of a new locus for autosomal recessive Charcot-Marie-Tooth disease with focally folded myelin on chromosome 11p15. Genomics 1999; 62:344.</a></li><li><a class="nounderline abstract_t">Hirano R, Takashima H, Umehara F, et al. SET binding factor 2 (SBF2) mutation causes CMT4B with juvenile onset glaucoma. Neurology 2004; 63:577.</a></li><li><a class="nounderline abstract_t">Senderek J, Bergmann C, Weber S, et al. Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum Mol Genet 2003; 12:349.</a></li><li><a class="nounderline abstract_t">Azzedine H, Bolino A, Taïeb T, et al. Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. Am J Hum Genet 2003; 72:1141.</a></li><li><a class="nounderline abstract_t">Kiwaki T, Umehara F, Takashima H, et al. Hereditary motor and sensory neuropathy with myelin folding and juvenile onset glaucoma. Neurology 2000; 55:392.</a></li><li><a class="nounderline abstract_t">Gambardella A, Bolino A, Muglia M, et al. Genetic heterogeneity in autosomal recessive hereditary motor and sensory neuropathy with focally folded myelin sheaths (CMT4B). Neurology 1998; 50:799.</a></li><li><a class="nounderline abstract_t">Conforti FL, Muglia M, Mazzei R, et al. A new SBF2 mutation in a family with recessive demyelinating Charcot-Marie-Tooth (CMT4B2). Neurology 2004; 63:1327.</a></li><li><a class="nounderline abstract_t">Nakhro K, Park JM, Hong YB, et al. SET binding factor 1 (SBF1) mutation causes Charcot-Marie-Tooth disease type 4B3. Neurology 2013; 81:165.</a></li><li><a class="nounderline abstract_t">LeGuern E, Guilbot A, Kessali M, et al. Homozygosity mapping of an autosomal recessive form of demyelinating Charcot-Marie-Tooth disease to chromosome 5q23-q33. Hum Mol Genet 1996; 5:1685.</a></li><li><a class="nounderline abstract_t">Gabreëls-Festen A, van Beersum S, Eshuis L, et al. Study on the gene and phenotypic characterisation of autosomal recessive demyelinating motor and sensory neuropathy (Charcot-Marie-Tooth disease) with a gene locus on chromosome 5q23-q33. J Neurol Neurosurg Psychiatry 1999; 66:569.</a></li><li><a class="nounderline abstract_t">Guilbot A, Ravisé N, Bouhouche A, et al. Genetic, cytogenetic and physical refinement of the autosomal recessive CMT linked to 5q31-q33: exclusion of candidate genes including EGR1. Eur J Hum Genet 1999; 7:849.</a></li><li><a class="nounderline abstract_t">Varley TL, Bourque PR, Baker SK. Phenotypic variability of CMT4C in a French-Canadian kindred. Muscle Nerve 2015; 52:444.</a></li><li><a class="nounderline abstract_t">Laššuthová P, Mazanec R, Vondráček P, et al. High frequency of SH3TC2 mutations in Czech HMSN I patients. Clin Genet 2011; 80:334.</a></li><li><a class="nounderline abstract_t">Colomer J, Gooding R, Angelicheva D, et al. Clinical spectrum of CMT4C disease in patients homozygous for the p.Arg1109X mutation in SH3TC2. Neuromuscul Disord 2006; 16:449.</a></li><li><a class="nounderline abstract_t">Jerath NU, Mankodi A, Crawford TO, et al. Charcot-Marie-Tooth Disease type 4C: Novel mutations, clinical presentations, and diagnostic challenges. Muscle Nerve 2018; 57:749.</a></li><li><a class="nounderline abstract_t">Lee AJ, Nam SH, Park JM, et al. Compound heterozygous mutations of SH3TC2 in Charcot-Marie-Tooth disease type 4C patients. J Hum Genet 2019; 64:961.</a></li><li><a class="nounderline abstract_t">Arntzen KA, Høyer H, Ørstavik K, et al. Charcot-Marie-Tooth disease type 4C in Norway: Clinical characteristics, mutation spectrum and minimum prevalence. Neuromuscul Disord 2018; 28:639.</a></li><li><a class="nounderline abstract_t">Senderek J, Bergmann C, Stendel C, et al. Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. Am J Hum Genet 2003; 73:1106.</a></li><li><a class="nounderline abstract_t">Azzedine H, Ravisé N, Verny C, et al. Spine deformities in Charcot-Marie-Tooth 4C caused by SH3TC2 gene mutations. Neurology 2006; 67:602.</a></li><li><a class="nounderline abstract_t">Kalaydjieva L, Hallmayer J, Chandler D, et al. Gene mapping in Gypsies identifies a novel demyelinating neuropathy on chromosome 8q24. Nat Genet 1996; 14:214.</a></li><li><a class="nounderline abstract_t">Kalaydjieva L, Gresham D, Gooding R, et al. N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. Am J Hum Genet 2000; 67:47.</a></li><li><a class="nounderline abstract_t">Guilbot A, Williams A, Ravisé N, et al. A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of Charcot-Marie-Tooth disease. Hum Mol Genet 2001; 10:415.</a></li><li><a class="nounderline abstract_t">Rogers T, Chandler D, Angelicheva D, et al. A novel locus for autosomal recessive peripheral neuropathy in the EGR2 region on 10q23. Am J Hum Genet 2000; 67:664.</a></li><li><a class="nounderline abstract_t">Sevilla T, Martínez-Rubio D, Márquez C, et al. Genetics of the Charcot-Marie-Tooth disease in the Spanish Gypsy population: the hereditary motor and sensory neuropathy-Russe in depth. Clin Genet 2013; 83:565.</a></li><li><a class="nounderline abstract_t">Hantke J, Chandler D, King R, et al. A mutation in an alternative untranslated exon of hexokinase 1 associated with hereditary motor and sensory neuropathy -- Russe (HMSNR). Eur J Hum Genet 2009; 17:1606.</a></li><li><a class="nounderline abstract_t">De Sandre-Giovannoli A, Delague V, Hamadouche T, et al. Homozygosity mapping of autosomal recessive demyelinating Charcot-Marie-Tooth neuropathy (CMT4H) to a novel locus on chromosome 12p11.21-q13.11. J Med Genet 2005; 42:260.</a></li><li><a class="nounderline abstract_t">Stendel C, Roos A, Deconinck T, et al. Peripheral nerve demyelination caused by a mutant Rho GTPase guanine nucleotide exchange factor, frabin/FGD4. Am J Hum Genet 2007; 81:158.</a></li><li><a class="nounderline abstract_t">Fabrizi GM, Taioli F, Cavallaro T, et al. Further evidence that mutations in FGD4/frabin cause Charcot-Marie-Tooth disease type 4H. Neurology 2009; 72:1160.</a></li><li><a class="nounderline abstract_t">Chow CY, Zhang Y, Dowling JJ, et al. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 2007; 448:68.</a></li><li><a class="nounderline abstract_t">Zhang X, Chow CY, Sahenk Z, et al. Mutation of FIG4 causes a rapidly progressive, asymmetric neuronal degeneration. Brain 2008; 131:1990.</a></li><li><a class="nounderline abstract_t">Echaniz-Laguna A, Ghezzi D, Chassagne M, et al. SURF1 deficiency causes demyelinating Charcot-Marie-Tooth disease. Neurology 2013; 81:1523.</a></li><li><a class="nounderline abstract_t">Ylikallio E, Woldegebriel R, Tumiati M, et al. MCM3AP in recessive Charcot-Marie-Tooth neuropathy and mild intellectual disability. Brain 2017; 140:2093.</a></li><li><a class="nounderline abstract_t">Berciano J, García A, Gallardo E, et al. Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review. J Neurol 2017; 264:1655.</a></li><li><a class="nounderline abstract_t">Liu L, Zhang R. Intermediate Charcot-Marie-Tooth disease. Neurosci Bull 2014; 30:999.</a></li><li><a class="nounderline abstract_t">Davis CJ, Bradley WG, Madrid R. The peroneal muscular atrophy syndrome: clinical, genetic, electrophysiological and nerve biopsy studies. I. Clinical, genetic and electrophysiological findings and classification. J Genet Hum 1978; 26:311.</a></li><li><a class="nounderline abstract_t">Verhoeven K, Villanova M, Rossi A, et al. Localization of the gene for the intermediate form of Charcot-Marie-Tooth to chromosome 10q24.1-q25.1. Am J Hum Genet 2001; 69:889.</a></li><li><a class="nounderline abstract_t">Jordanova A, Thomas FP, Guergueltcheva V, et al. Dominant intermediate Charcot-Marie-Tooth type C maps to chromosome 1p34-p35. Am J Hum Genet 2003; 73:1423.</a></li><li><a class="nounderline abstract_t">Jordanova A, Irobi J, Thomas FP, et al. Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nat Genet 2006; 38:197.</a></li><li><a class="nounderline abstract_t">McLaughlin HM, Sakaguchi R, Liu C, et al. Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy. Am J Hum Genet 2010; 87:560.</a></li><li><a class="nounderline abstract_t">Kim HJ, Hong YB, Park JM, et al. Mutations in the PLEKHG5 gene is relevant with autosomal recessive intermediate Charcot-Marie-Tooth disease. Orphanet J Rare Dis 2013; 8:104.</a></li><li><a class="nounderline abstract_t">Azzedine H, Zavadakova P, Planté-Bordeneuve V, et al. PLEKHG5 deficiency leads to an intermediate form of autosomal-recessive Charcot-Marie-Tooth disease. Hum Mol Genet 2013; 22:4224.</a></li><li><a class="nounderline abstract_t">Pareyson D. Differential diagnosis of Charcot-Marie-Tooth disease and related neuropathies. Neurol Sci 2004; 25:72.</a></li><li><a class="nounderline abstract_t">Zanette G, Fabrizi GM, Taioli F, et al. Nerve ultrasound findings differentiate Charcot-Marie-Tooth disease (CMT) 1A from other demyelinating CMTs. Clin Neurophysiol 2018; 129:2259.</a></li><li><a class="nounderline abstract_t">Karakis I, Gregas M, Darras BT, et al. Clinical correlates of Charcot-Marie-Tooth disease in patients with pes cavus deformities. Muscle Nerve 2013; 47:488.</a></li><li class="breakAll">Bird TD. Charcot-Marie-Tooth hereditary neuropathy overview. GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK1358/ (Accessed on July 12, 2017).</li><li><a class="nounderline abstract_t">Amato AA, Reilly MM. The death panel for Charcot-Marie-Tooth panels. Ann Neurol 2011; 69:1.</a></li><li><a class="nounderline abstract_t">Andersson PB, Yuen E, Parko K, So YT. Electrodiagnostic features of hereditary neuropathy with liability to pressure palsies. Neurology 2000; 54:40.</a></li><li><a class="nounderline abstract_t">Cortese A, Zhu Y, Rebelo AP, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet 2020; 52:473.</a></li><li><a class="nounderline abstract_t">Green P, Wiseman M, Crow YJ, et al. Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54. Am J Hum Genet 2010; 86:485.</a></li><li><a class="nounderline abstract_t">Holling T, Nampoothiri S, Tarhan B, et al. Novel biallelic variants expand the SLC5A6-related phenotypic spectrum. Eur J Hum Genet 2022; 30:439.</a></li></ol></div><div id="topicVersionRevision">Topic 6220 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Dyck PJ. Neuronal atrophy and degeneration predominantly affecting peripheral sensory and autonomic neurons. In: Peripheral Neuropathy, Dyck PJ, Thomas PK, Lambert EH, et al (Eds), WB Saunders, Philadelphia 1984. Vol 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31760652" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Schwann Cell and the Pathogenesis of Charcot-Marie-Tooth Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022584" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Charcot-Marie-Tooth polyneuropathy: duplication, gene dosage, and genetic heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10648431" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Charcot-Marie-Tooth disease type 1: molecular pathogenesis to gene therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23801417" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Inherited neuropathies: clinical overview and update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28678038" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : New developments in Charcot-Marie-Tooth neuropathy and related diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21280073" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Charcot-Marie-Tooth disease subtypes and genetic testing strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30257968" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Genetic profile and onset features of 1005 patients with Charcot-Marie-Tooth disease in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24018473" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical implications of genetic advances in Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26849231" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epidemiologic Study of Charcot-Marie-Tooth Disease: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10737979" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Screening for mutations in the peripheral myelin genes PMP22, MPZ and Cx32 (GJB1) in Russian Charcot-Marie-Tooth neuropathy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30340945" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Retrospective study of 75 children with peripheral inherited neuropathy: Genotype-phenotype correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25430934" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2747736" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Longitudinal conduction studies in hereditary motor and sensory neuropathy type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8413959" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pregnancy and delivery in Charcot-Marie-Tooth disease type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6265822" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pooled European series of hereditary peripheral neuropathies in infancy and childhood. A "correspondence work shop" report of the European Federation of Child Neurology Societies (EFCNS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10869062" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18852440" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Motor axon loss is associated with hand dysfunction in Charcot-Marie-Tooth disease 1a.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1513466" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Autosomal recessive form of hereditary motor and sensory neuropathy type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2245309" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : X-linked dominant hereditary motor and sensory neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8430694" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Linkage localization of X-linked Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8266101" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Connexin mutations in X-linked Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9096765" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Diagnosis of CMT1A duplications and HNPP deletions by interphase FISH: implications for testing in the cytogenetics laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10775544" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mutation-dependent alteration in cellular distribution of peripheral myelin protein 22 in nerve biopsies from Charcot-Marie-Tooth type 1A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11214130" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Charcot-Marie-Tooth disease and sleep apnoea syndrome: a family study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18559462" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Increased prevalence of obstructive sleep apnoea in patients with Charcot-Marie-Tooth disease: a case control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1322507" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hereditary neuropathy with liability to pressure palsies in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10227632" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Spectrum of clinical and electrophysiologic features in HNPP patients with the 17p11.2 deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24668782" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical, electrophysiological, and molecular findings in early onset hereditary neuropathy with liability to pressure palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12439896" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Family with inflammatory demyelinating polyneuropathy and the HNPP 17p12 deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24726093" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical, neurophysiological and pathological findings of HNPP patients with 17p12 deletion: a single-centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25042093" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pain in hereditary neuropathy with liability to pressure palsy: an association with fibromyalgia syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26773980" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Low back pain with radicular symptoms as a presentation of hereditary neuropathy with liability to pressure palsies: the diagnostic challenge of an atypical presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344349" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Central nervous system involvement in hereditary neuropathy with liability to pressure palsies: description of a large family with this association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190957" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : CNS involvement in hereditary neuropathy with pressure palsies (HNPP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6185651" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hereditary neuropathy with liability to pressure palsies. Report of two families and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10680781" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hereditary recurrent focal neuropathies: clinical and molecular features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7944298" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prevalence of the 1.5-Mb 17p deletion in families with hereditary neuropathy with liability to pressure palsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7944298" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prevalence of the 1.5-Mb 17p deletion in families with hereditary neuropathy with liability to pressure palsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620487" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Stoichiometric alteration of PMP22 protein determines the phenotype of hereditary neuropathy with liability to pressure palsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11494267" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Diagnostic strategy for familial and sporadic cases of neuropathy associated with 17p11.2 deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24339129" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Abnormal junctions and permeability of myelin in PMP22-deficient nerves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28407266" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hereditary neuropathy with liability to pressure palsy in patients under 30 years old: Neurophysiological data and proposed electrodiagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10586224" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Historical perspective of defining Charcot-Marie-Tooth type 1B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7693129" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12477701" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25299278" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Charcot-Marie-Tooth disease and other inherited neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14711881" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Phenotypic clustering in MPZ mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406984" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Novel mutation in the myelin protein zero gene in a family with intermediate hereditary motor and sensory neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20544920" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Charcot-Marie-Tooth disease with intermediate conduction velocities caused by a novel mutation in the MPZ gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10704451" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : P(0) glycoprotein overexpression causes congenital hypomyelination of peripheral nerves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9055797" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hereditary demyelinating neuropathy of infancy. A genetically complex syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22275255" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Increased gene dosage of myelin protein zero causes Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17030746" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Skin biopsies demonstrate MPZ splicing abnormalities in Charcot-Marie-Tooth neuropathy 1B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9788273" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Myelin protein zero and membrane adhesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11935267" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Altered trafficking and adhesion function of MPZ mutations and phenotypes of Charcot-Marie-Tooth disease 1B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18209201" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : MPZ mutation G123S characterization: evidence for a complex pathogenesis in CMT disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11713717" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Mapping of Charcot-Marie-Tooth disease type 1C to chromosome 16p identifies a novel locus for demyelinating neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525712" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9537424" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7139106" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Charcot-Marie-Tooth disease with sensorineural hearing loss--an autosomal dominant trait.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10330345" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A unique point mutation in the PMP22 gene is associated with Charcot-Marie-Tooth disease and deafness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12566280" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10553995" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The Roussy-Lévy family: from the original description to the gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9543325" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Roussy-Lévy syndrome is a phenotypic variant of Charcot-Marie-Tooth syndrome IA associated with a duplication on chromosome 17p11.2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10716658" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Inherited peripheral neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043782" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Axonal Charcot-Marie-Tooth disease: the fog is slowly lifting!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18495953" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Late-onset hereditary axonal neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10441578" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A locus for an axonal form of autosomal recessive Charcot-Marie-Tooth disease maps to chromosome 1q21.2-q21.3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17347251" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Autosomal recessive axonal Charcot-Marie-Tooth disease (ARCMT2): phenotype-genotype correlations in 13 Moroccan families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17410579" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Autosomal-recessive and X-linked forms of hereditary motor and sensory neuropathy in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22577229" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20163430" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Mechanisms of disease and clinical features of mutations of the gene for mitofusin 2: an important cause of hereditary peripheral neuropathy with striking clinical variability in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15064763" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043786" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21508331" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : MFN2 mutations cause severe phenotypes in most patients with CMT2A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21715711" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26114802" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : MFN2 deletion of exons 7 and 8: founder mutation in the UK population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11389829" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15136675" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Absence of KIF1B mutation in a large Turkish CMT2A family suggests involvement of a second gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9008488" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Hereditary motor and sensory neuropathy IIB: clinical and electrodiagnostic characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12545426" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12682323" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The gene for HMSN2C maps to 12q23-24: a region of neuromuscular disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668982" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Confirmation of a hereditary motor and sensory neuropathy IIC locus at chromosome 12q23-q24.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20037588" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115951" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : CMT2C with vocal cord paresis associated with short stature and mutations in the TRPV4 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8872480" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Autosomal dominant Charcot-Marie-Tooth axonal neuropathy mapped on chromosome 7p (CMT2D).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12690580" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10841809" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11220745" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20039262" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : A novel recessive Nefl mutation causes a severe, early-onset axonal neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17052987" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Charcot-Marie-Tooth disease type 2E, a disorder of the cytoskeleton.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11528513" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2F) maps to chromosome 7q11-q21.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15122254" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764043" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Charcot-Marie-Tooth neuropathy type 2 and P0 point mutations: two novel amino acid substitutions (Asp61Gly; Tyr119Cys) and a possible "hotspot" on Thr124Met.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10329755" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Axonal phenotype of Charcot-Marie-Tooth disease associated with a mutation in the myelin protein zero gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071056" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11080237" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : An axonal form of Charcot-Marie-Tooth disease showing distinctive features in association with mutations in the peripheral myelin protein zero gene (Thr124Met or Asp75Val).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12707075" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Phenotypical features of a Moroccan family with autosomal recessive Charcot-Marie-Tooth disease associated with the S194X mutation in the GDAP1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18231710" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : A novel GDAP1 Q218E mutation in autosomal dominant Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20685671" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The GST domain of GDAP1 is a frequent target of mutations in the dominant form of axonal Charcot Marie Tooth type 2K.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15021985" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2L) maps to chromosome 12q24.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15122253" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636067" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Two novel mutations in dynamin-2 cause axonal Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18560793" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Magnetic resonance imaging findings of leg musculature in Charcot-Marie-Tooth disease type 2 due to dynamin 2 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533912" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Dominant intermediate Charcot-Marie-Tooth neuropathy maps to chromosome 19p12-p13.2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15731758" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14985381" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Autosomal dominant axonal Charcot-Marie-Tooth disease type 2 (CMT2G) maps to chromosome 12q12-q13.3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27686364" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Charcot-Marie-Tooth disease type 2G redefined by a novel mutation in LRSAM1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25439726" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Truncating and missense mutations in IGHMBP2 cause Charcot-Marie Tooth disease type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26136520" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Recessive hereditary motor and sensory neuropathy caused by IGHMBP2 gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26991897" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth disease type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415211" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Characterising the phenotype and mode of inheritance of patients with inherited peripheral neuropathies carrying MME mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22933740" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Genetic dysfunction of MT-ATP6 causes axonal Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29499166" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Mutations in ATP1A1 Cause Dominant Charcot-Marie-Tooth Type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19539237" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Diagnosis, natural history, and management of Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11898586" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : The genetic convergence of Charcot-Marie-Tooth disease types 1 and 2 and the role of genetics in sporadic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17159110" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Proof of genetic heterogeneity in X-linked Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10732813" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Mutations in the X-linked form of Charcot-Marie-Tooth disease in the French population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353473" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : CMT1X phenotypes represent loss of GJB1 gene function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29998508" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Genetic and phenotypic profile of 112 patients with X-linked Charcot-Marie-Tooth disease type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21282593" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : A retrospective review of X-linked Charcot-Marie-Tooth disease in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23400245" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : The central nervous system phenotype of X-linked Charcot-Marie-Tooth disease: a transient disorder of children and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21900630" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Recurrent stroke-like episodes in X-linked Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12325071" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Transient central nervous system white matter abnormality in X-linked Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14663027" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : The CNS phenotype of X-linked Charcot-Marie-Tooth disease: more than a peripheral problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30196252" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : X linked Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence for an association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8255457" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Intermediate nerve conduction velocities define X-linked Charcot-Marie-Tooth neuropathy families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1674639" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Heterogeneity in X-linked recessive Charcot-Marie-Tooth neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1557086" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : X-linked recessive Charcot-Marie-Tooth neuropathy: clinical and genetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26385972" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : A Review of X-linked Charcot-Marie-Tooth Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27438001" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Whole Genome Sequencing Identifies a 78 kb Insertion from Chromosome 8 as the Cause of Charcot-Marie-Tooth Neuropathy CMTX3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29626178" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Unique clinical and neurophysiologic profile of a cohort of children with CMTX3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3856385" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : X-linked motor-sensory neuropathy type-II with deafness and mental retardation: a new disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23217327" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Cowchock syndrome is associated with a mutation in apoptosis-inducing factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15955956" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : A novel locus for X-linked recessive CMT with deafness and optic neuropathy maps to Xq21.32-q24.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17701900" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Mutations in PRPS1, which encodes the phosphoribosyl pyrophosphate synthetase enzyme critical for nucleotide biosynthesis, cause hereditary peripheral neuropathy with hearing loss and optic neuropathy (cmtx5).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23297365" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : A new locus for X-linked dominant Charcot-Marie-Tooth disease (CMTX6) is caused by mutations in the pyruvate dehydrogenase kinase isoenzyme 3 (PDK3) gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3467805" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : The hypertrophic forms of hereditary motor and sensory neuropathy. A study of hypertrophic Charcot-Marie-Tooth disease (HMSN type I) and Dejerine-Sottas disease (HMSN type III) in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15469949" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Clinicopathological and genetic study of early-onset demyelinating neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10211478" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Recessive inheritance of a new point mutation of the PMP22 gene in Dejerine-Sottas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9544841" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Novel mutations of the peripheral myelin protein 22 gene in two pedigrees with Dejerine-Sottas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10371530" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Novel missense mutation in the early growth response 2 gene associated with Dejerine-Sottas syndrome phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11523566" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : EGR2 mutation R359W causes a spectrum of Dejerine-Sottas neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11133365" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Periaxin mutations cause recessive Dejerine-Sottas neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2835709" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Congenital absence of peripheral myelin: abnormal Schwann cell development causes lethal arthrogryposis multiplex congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9044408" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Congenital hypomyelinating neuropathy: a reversible case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9165518" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Unexpected recovery in a newborn with severe hypomyelinating neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10207934" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Congenital hypomyelinating neuropathy: two patients with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10319895" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Congenital hypomyelination due to myelin protein zero Q215X mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184631" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : A novel MPZ gene mutation in congenital neuropathy with hypomyelination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20621479" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Novel MPZ mutations and congenital hypomyelinating neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11354824" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Denaturing high-performance liquid chromatography of the myotubularin-related 2 gene (MTMR2) in unrelated patients with Charcot-Marie-Tooth disease suggests a low frequency of mutation in inherited neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11354824" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Denaturing high-performance liquid chromatography of the myotubularin-related 2 gene (MTMR2) in unrelated patients with Charcot-Marie-Tooth disease suggests a low frequency of mutation in inherited neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8268915" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Linkage of a locus (CMT4A) for autosomal recessive Charcot-Marie-Tooth disease to chromosome 8q.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11743579" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11743580" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15772096" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : GDAP1, the protein causing Charcot-Marie-Tooth disease type 4A, is expressed in neurons and is associated with mitochondria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12566285" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Mutations in the ganglioside-induced differentiation-associated protein-1 (GDAP1) gene in intermediate type autosomal recessive Charcot-Marie-Tooth neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21692914" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Two recessive intermediate Charcot-Marie-Tooth patients with GDAP1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8817346" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Localization of a gene responsible for autosomal recessive demyelinating neuropathy with focally folded myelin sheaths to chromosome 11q23 by homozygosity mapping and haplotype sharing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673338" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Genetic refinement and physical mapping of the CMT4B gene on chromosome 11q22.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8628474" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Autosomal recessive hereditary motor and sensory neuropathy with focally folded myelin sheaths: clinical, electrophysiologic, and genetic aspects of a large family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10802647" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31070812" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : A multicenter retrospective study of charcot-marie-tooth disease type 4B (CMT4B) associated with mutations in myotubularin-related proteins (MTMRs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10644431" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Identification of a new locus for autosomal recessive Charcot-Marie-Tooth disease with focally folded myelin on chromosome 11p15.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304601" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : SET binding factor 2 (SBF2) mutation causes CMT4B with juvenile onset glaucoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12554688" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12687498" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10932274" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Hereditary motor and sensory neuropathy with myelin folding and juvenile onset glaucoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521281" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Genetic heterogeneity in autosomal recessive hereditary motor and sensory neuropathy with focally folded myelin sheaths (CMT4B).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477569" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : A new SBF2 mutation in a family with recessive demyelinating Charcot-Marie-Tooth (CMT4B2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23749797" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : SET binding factor 1 (SBF1) mutation causes Charcot-Marie-Tooth disease type 4B3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8894708" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Homozygosity mapping of an autosomal recessive form of demyelinating Charcot-Marie-Tooth disease to chromosome 5q23-q33.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10209165" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Study on the gene and phenotypic characterisation of autosomal recessive demyelinating motor and sensory neuropathy (Charcot-Marie-Tooth disease) with a gene locus on chromosome 5q23-q33.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10602360" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Genetic, cytogenetic and physical refinement of the autosomal recessive CMT linked to 5q31-q33: exclusion of candidate genes including EGR1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25737037" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Phenotypic variability of CMT4C in a French-Canadian kindred.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21291453" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : High frequency of SH3TC2 mutations in Czech HMSN I patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16806930" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Clinical spectrum of CMT4C disease in patients homozygous for the p.Arg1109X mutation in SH3TC2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28981955" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Charcot-Marie-Tooth Disease type 4C: Novel mutations, clinical presentations, and diagnostic challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31227790" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Compound heterozygous mutations of SH3TC2 in Charcot-Marie-Tooth disease type 4C patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30001926" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Charcot-Marie-Tooth disease type 4C in Norway: Clinical characteristics, mutation spectrum and minimum prevalence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14574644" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16924012" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Spine deformities in Charcot-Marie-Tooth 4C caused by SH3TC2 gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8841199" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Gene mapping in Gypsies identifies a novel demyelinating neuropathy on chromosome 8q24.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10831399" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157804" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10915613" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : A novel locus for autosomal recessive peripheral neuropathy in the EGR2 region on 10q23.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22978647" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Genetics of the Charcot-Marie-Tooth disease in the Spanish Gypsy population: the hereditary motor and sensory neuropathy-Russe in depth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19536174" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : A mutation in an alternative untranslated exon of hexokinase 1 associated with hereditary motor and sensory neuropathy -- Russe (HMSNR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15744041" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Homozygosity mapping of autosomal recessive demyelinating Charcot-Marie-Tooth neuropathy (CMT4H) to a novel locus on chromosome 12p11.21-q13.11.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17564972" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Peripheral nerve demyelination caused by a mutant Rho GTPase guanine nucleotide exchange factor, frabin/FGD4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332693" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Further evidence that mutations in FGD4/frabin cause Charcot-Marie-Tooth disease type 4H.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17572665" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18556664" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Mutation of FIG4 causes a rapidly progressive, asymmetric neuronal degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24027061" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : SURF1 deficiency causes demyelinating Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28633435" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : MCM3AP in recessive Charcot-Marie-Tooth neuropathy and mild intellectual disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28364294" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25326399" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Intermediate Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/752065" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : The peroneal muscular atrophy syndrome: clinical, genetic, electrophysiological and nerve biopsy studies. I. Clinical, genetic and electrophysiological findings and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533914" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Localization of the gene for the intermediate form of Charcot-Marie-Tooth to chromosome 10q24.1-q25.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14606043" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Dominant intermediate Charcot-Marie-Tooth type C maps to chromosome 1p34-p35.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16429158" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20920668" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23844677" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : Mutations in the PLEKHG5 gene is relevant with autosomal recessive intermediate Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23777631" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : PLEKHG5 deficiency leads to an intermediate form of autosomal-recessive Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15221625" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Differential diagnosis of Charcot-Marie-Tooth disease and related neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30216910" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Nerve ultrasound findings differentiate Charcot-Marie-Tooth disease (CMT) 1A from other demyelinating CMTs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460299" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Clinical correlates of Charcot-Marie-Tooth disease in patients with pes cavus deformities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460299" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : Clinical correlates of Charcot-Marie-Tooth disease in patients with pes cavus deformities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21280068" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : The death panel for Charcot-Marie-Tooth panels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10636123" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Electrodiagnostic features of hereditary neuropathy with liability to pressure palsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32367058" id="rid212" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>213 : Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20206331" id="rid213" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>214 : Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35013551" id="rid214" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>215 : Novel biallelic variants expand the SLC5A6-related phenotypic spectrum.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
